Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and/or Corticosteroid Therapy, the INTERACT study: A Multicenter International Observational Study

Marwa Amer [1,2,*], Mohammed Bawazeer [3], Khalid Maghrabi [2,3], Ahmed Mohamed Kamal [4],Abid Butt [3], Talal Dahhan [2,3], Eiad Kseibi [3], Mohammed Abujazar [3], Razan Alghunaim [1], Muath Rabee [3], Maal Abualkhair [3], Ali Al-Janoubi [3], Abeer Turki AlFirm [5], Syed Moazzum Khurshid [3] Ognjen Gajic, MD[6] ,Allan J. Walkey, MD[7], Jarrod M Mosier[8], Igor Borisovich Zabolotskikh[9], Oscar Y Gavidia[10], Santiago Y. Teruel [11], Michael A. Bernstein[12], Karen Boman[13], Vishakha K. Kumar, MD, MBA[13], Vikas Bansal, MBBS, MPH[6] , Rahul Kashyap, MBBS, MBA[6]

¥ On behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group

[1] Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

[2] College of Medicine, Alfaisal University

[3] Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

[4] Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University

[5] Biostatistics, Epidemiology & Scientific Computing Department

[6] Mayo Clinic – Rochester, United States of America

[7]Boston University School of Medicine, United States of America

[8] Banner University Medical Center-Tucson, United States of America

[9] Kuban State Medical University with affiliation Territorial Hospital #2, Russia

[10] Clinica Medical SAS, Columbia

[11] Hospital Universitario La Paz, Spain

[12] Stamford Health, United States of America

[13] Society of Critical Care Medicine, United States of America

*Corresponding author at: King Faisal Specialist Hospital & Research Center, Pharmaceutical Care

26 Division (MBC # 11), PO Box 3354, Riyadh, 11211, Tel: +966114647272 Ext 70836 or 48030

27 Email address: mamer@kfshrc.edu.sa

28 The VIRUS Registry is supported, in part, by the Gordon and Betty Moore Foundation, and Janssen Research

29 & Development, LLC

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Abstract

Objectives: To compare the clinical characteristics and outcomes of critically ill coronavirus disease (COVID-19) patients requiring mechanical ventilation (MV), receiving interleukin-6 receptor (IL-6R) antagonists, steroids, or a combination of both.

Design: An international, multicenter, observational study derived from the COVID-2019 Viral Infection and Respiratory Illness University Study (VIRUS) registry and conducted through the Discovery Network, the Society of Critical Care Medicine. Marginal structural modeling was used to adjust for time-dependent confounders, and observations were weighted using the inverse probability of treatment weight. Sensitivity analysis was conducted to emulate a target trial design.

Setting: 168 hospitals in 16 countries.

Patients: adult ICU patients (≥ 18 years) requiring MV for COVID-19 between March 01, 2020, and January 10, 2021.

Intervention: None.

Measurements and Main Results: A total of 860 patients met eligibility criteria: 589 received steroids, 170 IL-6R antagonists, and 101 combination therapy, and the groups were balanced after adjustment. The median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR: 6–14 mg); 80.8% received low-dose and 19.2% high-dose steroids (> 15 mg/day of dexamethasone or equivalent). The median C-reactive protein level was > 75 mg/L in majority of our cohort. The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6R antagonists (ß= 0.62, 95% CI -1.54, 2.78 for low-dose steroid; ß= -1.19, 95% CI -3.85, 1.47 for high-dose steroid). The use of IL-6R antagonists alone or in combination was not associated with a significant difference in 28-day

mortality compared to steroids alone (adjusted odds ratio [95% CI]): IL-6R antagonists alone (0.68 [0.44,1.07]), combination (1.07 [0.67,1.7]). There was no difference in hospital mortality compared to steroids alone (aOR 0.68, 95% CI 0.43,1.09 for IL6-R antagonist, aOR 1.23, 95 % CI 0.72,2.11 for combination). The findings of sensitivity analysis were consistent with the primary analysis. The rate of liver dysfunction was higher in the IL-6R antagonist (p=0.038), while the rate of bacteremia did not differ among the three groups.

Conclusions: We observed no difference in outcomes between mechanically ventilated adult ICU patients who received IL-6R antagonists, steroids, or combination therapy and those who received IL-6R antagonists or low- or high-dose steroids. Further trials are needed to evaluate high-dose steroids as substitutes for IL-6R antagonists in resource-limited settings.

Keywords: interleukin-6, interleukin-6 receptor antagonist, steroid, critical care, coronavirus disease 2019, mechanical ventilation

Word count : text: 4198 , references: 40, Tables and Figures: 6

Background

Severe coronavirus disease 2019 (COVID-19) can manifest as rapid decompensation and respiratory failure with elevated inflammatory markers, resulting in cytokine release syndrome, for which interleukin-6 receptor (IL-6R) antagonists are approved treatments [1-4]. An interest in IL-6R antagonists and corticosteroids has increased recently due to their potential role as immunomodulators in the treatment of cytokine storms related to COVID-19 [5]. Therefore, the use of these agents has gained traction, and several clinical trials have shown variable results with IL-6R antagonists [6-9]. In view of the results from the International Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) and the Randomized Evaluation of COVID-19 Therapy (RECOVERY), guidelines from the National Institutes of Health and the Infectious Disease Society of America conditionally suggest the use of tocilizumab and sarilumab in combination with steroids (low-dose dexamethasone, 6 mg daily for 10 days) for patients who were admitted to the ICU and exhibited rapid progression of respiratory failure or high inflammatory markers [9-12]. Therefore, it is unclear whether this combination provides a synergistic effect compared to monotherapy with either agent. Moreover, data with other steroid regimen are limited (high-dose dexamethasone, 20 mg IV daily) which commonly used for non-COVID-19 acute respiratory distress syndrome (ARDS), and maybe utilized for COVID-19 ARDS as well [13]. We sought to describe the clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving monotherapy with an IL-6R antagonist or corticosteroid versus combination therapy with both [the **INTERACT** study: I**NTER**leukin-6 antagonist **A**nd **C**orticosteroid **T**herapy] using the data from the largest COVID-19 registry. In addition, we provided further insights into sarilumab and the utilizing pattern of multiple doses of steroids, including high-dose steroids.

Materials and Methods:

Data Source

Data for this ancillary study were derived from the VIRUS registry, an international, multicenter, cross-sectional observational study conducted through the Discovery Network, the research network of the Society of Critical Care Medicine (SCCM). The study is approved by the Ethics Committee (Project ID 2201053), SCCM Scientific

119 Review Committee, and SCCM Discovery Steering Committee. In some participating hospitals, verbal consent
120 was obtained whereas in other countries the requirement for patient consent was waived by local research
121 ethics committees. Local investigators were responsible for obtaining local approval in line with applicable
122 regulations. The study protocol was registered at ClinicalTrials.gov NCT04486521. No external funding was
123 provided for this study. The VIRUS is one of the largest registries that consecutively collects data on COVID-19
124 patients. As of January 10, 2021, a total of 49,058 hospital admissions and 8010 ICU admissions were recorded
125 (**eTable 1**). The details of this database have been described elsewhere [14-15]. The study is reported in
126 accordance with the STrengthening the Reporting of Observational Studies in Epidemiology (STROBE)
127 guidelines and follows the Risk Of Bias In Nonrandomized Studies - of Interventions (ROBINS-I) [16-17]

128 **Study Participants and Exposures**

129 Adults (≥ 18 years) patients were eligible if they were admitted to the ICU from March 01, 2020 to January 10,
130 2021, required invasive mechanical ventilation (iMV), had a reverse-transcriptase polymerase chain reaction
131 (PCR)-positive SARS-CoV-2 test, and received an IL-6R antagonist (tocilizumab/ sarilumab), a corticosteroid
132 (dexamethasone, hydrocortisone, methylprednisolone, or prednisone), or a combination of both. We excluded
133 patients who were < 17 years, pregnant, admitted repeatedly to ICU within the same hospital visit, on chronic
134 systemic steroid therapy prior to hospital admission, or died before receiving IL-6R antagonist or steroid
135 treatment. We stratified the population into three groups: patients who received 1) IL-6R antagonist, 2)
136 corticosteroid, and 3) combination therapy. The corticosteroid group was stratified further based on the
137 administered dexamethasone equivalent (mg) into high and low-dose groups. A high-dose steroid was defined
138 as > 15 mg/day of dexamethasone or dexamethasone equivalent [13]. Patients were followed until hospital
139 discharge, death, 28 days, or January 13th, 2021-the date on which the database was locked for the current
140 analysis.

141 **Data Collection**

142 The following variables that were collected on days 0 (the day of ICU admission), 1, 2, 3, 7, 14, 21, and 28 from
143 the electronic medical record according to established definitions and standard operating procedure (SOP)

144 from the VIRUS COVID-19 registry: demographics, laboratory values, microbiological results, concomitant
145 medications, MV duration, discharge status, and PaO_2(mm Hg)/FiO_2 (arterial partial pressure of oxygen divided
146 by the fractional inspired oxygen concentration; PF ratio). For the IL-6R antagonist, the timing of drug initiation
147 and its dose were recorded, and we only included the intravenous formulation. For the steroid, the timing of
148 drug initiation and its dose (as dexamethasone equivalents) were recorded. Data were collected online and
149 stored on a secure data server that runs the Mayo Clinic Research Electronic Data Capture (REDCap) web
150 application. The data quality was assessed routinely to ensure completeness and accuracy [18].

151 **Study Outcomes and Variable Definitions**

152 The primary outcome was ventilator-free days (VFD) from iMV at day 28 for those who received monotherapy
153 with an IL-6R antagonist or corticosteroid versus combination therapy. This outcome was chosen as a patient-
154 centered outcome and highly influenced by mortality [19]. Other secondary outcomes include 1) ICU mortality,
155 2) hospital mortality, 3) 28-day mortality, 4) hospital and ICU length of stay (LOS), 5) the median change in the
156 PF ratio, 6) percentage of adverse events (AEs) and secondary infections, and 7) biomarkers concentration
157 [ferritin, IL-6, D-dimer, fibrinogen, C-reactive protein [CRP], lactate dehydrogenase, and lymphocyte count).
158 Details on outcome definitions are provided in **eTable 2.**

159 **Statistical analysis**

160 The sample size was determined pragmatically, based on all available ICU patients in the VIRUS database who
161 received either IL-6R antagonists, steroids, or the combination therapy. Statistical analyses were performed
162 using R statistical software, V3.6.3 (Vienna, Austria). Counts and percentages were used to represent
163 categorical variables. Continuous data were summarized using means ± standard deviations (SDs) or medians
164 (interquartile ranges). The chi-square test of independence was used to compare the distribution categorical
165 variables and Kruskal–Wallis test and ANOVA were used to compare the distributions of continuous non-
166 normal and normal variables, respectively. Marginal structural models (MSM) were used to compare the three
167 regimens after adjusting for non-time and time-varying covariates [20]. Observations were weighted by the
168 inverse of the estimated probability of the individual receiving treatment in the observed sequence of

169 treatments, or the inverse probability of treatment weight (IPTW). Nonparametric modeling using generalized
170 boosted logistic regression (GBM) was used to estimate IPTWs with automatic handling of missing data (no
171 imputation for missing values) [21]. The TWANG package in R was used for this analysis. The distributions of
172 covariates were compared before and after applying propensity weights. The standardized mean difference
173 (SMD) was used to assess the balance of the pseudo-population using the Kolmogorov–Smirnov stop rule. The
174 average treatment effect (ATE) estimation method was used throughout the analysis on the entire sample.
175 Covariates included in model were judged as likely to influence patient outcome: age; sex; ethnicity;
176 asthma/chronic obstructive pulmonary disease (COPD); ARDS grade; history of diabetes, hypertension,
177 coronary heart disease, or congestive heart failure; the lowest FiO2; therapeutic anticoagulation;
178 hydroxychloroquine; azithromycin; and antivirals (including remdesivir); vasopressors; and neuromuscular
179 blockers. All analyses were performed using robust variance estimators to take the clustering within hospitals
180 and patients into account. Quasi-Poisson generalized linear modeling was used to compare the VFD after
181 weighting. Patients who died before 28-day were assigned zero VFD. The quasi-Poisson regression coefficients
182 were exponentiated to obtain the incidence rate ratio (IRR), which is the expected change in VF-days (ratio),
183 compared to the reference category. Quasibinomial generalized linear modeling was used to compare
184 mortality between the three groups. The weighted Kaplan–Maier estimator was used to compare the duration
185 of ICU stay. Patients who were still in the ICU at the end of the 28-day study period were censored at 28 days.
186 The log-rank test was used to compare survival before and after weighing. Cause-Specific Cox regression
187 analysis was used to assess factors associated with mortality at 28 days. Discharge and mortality were included
188 as competing risks.
189 We also performed one sensitivity and exploratory analyses. Sensitivity analysis was conducted to emulate a
190 target trial to reduce the immortal time bias. Eligible patients on MV were included if they received IL-6R
191 antagonists or steroids within ICU days 0 or 1. Patients who died within the first 48 hours were also excluded.
192 Those who get a treatment of interest after day 1 would be classified by the treatment they got in the first 48
193 hours (as in an intention-to-treat analysis in a randomized trial) [22]. In exploratory analyses of potential

194 factors associated with variation in VFD and mortality, we added Sequential Organ Failure Assessment (SOFA)
195 score quartile at ICU admission, and highest FiO2 to the base model.
196 Linear mixed modeling was used to compare the change in laboratory values and PF ratio between groups
197 after adjusting for the same covariates. Hypothesis testing was performed at 5% level of significance. Details
198 on statistical analysis are provided in **eFile 1**.

199 **Results**

200 A total of 23,783 patients were screened, 860 patients met the eligibility criteria. These patients were
201 classified as follows: 170 patients received only IL-6R antagonists, 589 received only steroids, and 101 received
202 both therapies. Eighty-eight patients were excluded because they were on systemic corticosteroids before
203 admission, and 728 patients did not receive steroids or IL-6R antagonists. In the sensitivity analysis to emulate
204 a target trial, a total of 562 patients fulfilled the inclusion criteria. Of these, 406 received steroids only (72.2%),
205 121 received IL6-R antagonists only (21.5%), and 35 received both therapies (6.23%) (**Figure 1**).

206 Overall Characteristics:

207 In unadjusted analysis, baseline covariates across groups were not balanced. IL-6R antagonist-treated patients
208 were younger (median 57.5 vs. 61.1 years in the steroid vs. 61.8 in the combination arm; p=0.009) and chronic
209 pulmonary diseases, excluding asthma (e.g., chronic bronchitis, COPD, emphysema, cystic fibrosis,
210 bronchiectasis, and interstitial lung disease), were more prevalent in the steroid group (59 [10.0%] vs. 7
211 [4.12%] in the IL-6R antagonist vs. 16 [15.8%] in the combination group, p=0.005). The ARDS was prevalent in
212 35.5% of steroid-treated patients, 14.7% in the IL-6R antagonist, and 36.6 % in combination therapy; the
213 majority of these patients had severe ARDS grades (PF ratio < 100). There was no significant difference in the
214 incidence of acute liver failure, and bacteremia among the three arms. After adjustments for baseline
215 covariates, the SMD was ~ 0.1 for all comparisons, which indicates that the three groups were balanced (**Table
216 1).** The median daily steroid dose was 7.5 mg dexamethasone equivalent (IQR 6 to 14 mg). Of these, 80.8%
217 received low-dose steroids, and 19.2% received high-dose steroids. Of the patients who received IL-6R

218 antagonists, the majority (84.5%) received only one dose of tocilizumab, and the second and third doses of
219 tocilizumab were administered to 13.1% and 2.3%, respectively. The majority of patients (84.7%) in the
220 sarilumab group received a single dose. The dosage range of tocilizumab was 600–800 mg and sarilumab was
221 200-400 mg (**Table 2**). Moreover, the matched patients received a comparable amounts of sedation,
222 neuromuscular blockers, and anticoagulation. Nine patients received anakinra and 123 patients received
223 remdesivir (14.3%). The CRP level was assessed in 413 patients and was consistently > 75 mg/L across all three
224 groups. Approximately 24 patients had IL-6 concentrations checked on ICU Day 0 and were the highest among
225 the combination group at baseline compared to the steroid or IL-6R antagonist groups. Additional details on
226 other comorbidities, ventilator and radiology characteristics, ICU supports, and biomarker levels on ICU Day 0
227 are included in the **eTable 3-10**

228 Primary Outcomes:

229 The use of IL-6R antagonists alone or in combination was not associated with a significant difference in VFDs
230 compared to using steroids alone (adjusted IRR [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83
231 [0.6,1.14]). The findings of the sensitivity analysis as a target trial approach were consistent with the primary
232 analysis; no difference was observed between IL-6R antagonists alone or in combination compared to using
233 steroids alone (aIRR [95% CI]): IL-6R antagonists (1.13 [0.87,1.45]), combination (0.64[0.34,1.23]) [**Figure 2A**].
234 Further analysis was performed stratified by steroid dose using linear regression analysis. No significant
235 differences were found between patients who were treated with low and high steroid doses and patients who
236 received IL-6R antagonists (ß = 0.62, 95% CI -1.54, 2.78; p=0.573 for low-dose steroid; ß = -1.19, 95% CI -3.85,
237 1.47; p=0.379 for high-dose steroid). Factors associated with higher odds of VFD were the non-use of
238 neuromuscular blockers, use of therapeutic anticoagulation, and low FiO_2 (**Table 3)**.

239 Secondary Outcomes:

240 There was no significant difference in 28-day mortality between patients treated with steroids or IL-6R
241 antagonists alone (aOR 0.68, 95 % CI 0.44, 1.07), or steroid treatment alone and combination therapy (aOR
242 1.07, 95% CI 0.67, 1.70). The findings of the sensitivity analysis as a target trial approach were consistent with

243 the primary analysis; no difference was observed between IL-6R antagonists alone or in combination compared
244 to using steroids alone. There was no difference in hospital mortality compared to steroids alone (aOR 0.68 ,
245 95% CI 0.43,1.09 for IL6-R antagonist, aOR 1.23, 95 % CI 0.72, 2.11 for combination) [**Figure 2B**]. Cause-specific
246 Cox proportional hazard regression was used to assess factors associated with mortality (**Figure 3, Panels A**
247 **and B**). Discharge and mortality were included as competing risks. The hazard of mortality was not significantly
248 different between patients who used IL-6R antagonists (HR = 0.9, p>0.05) or those who used both therapy (HR
249 = 0.84, p>0.05) and patients who used only steroids. Similarly, the hazard of ICU discharge was not significantly
250 different between patients who used IL-6R antagonists (HR = 1.4, p>0.05) or those who used both therapy (HR
251 = 0.0.85, p>0.05) and patients who used only steroids. The Cox proportional hazard model for ICU discharge
252 showed no significant difference in the probability of discharging alive from ICU in patients treated with IL-6R
253 antagonists (HR 1.36, 95% CI 0.95,1.93, p=0.089) or combination therapy (HR 0.85, 95% CI 0.54,1.34, p=0.484)
254 compared to those treated with steroids alone. Other variables with coefficients less than 1 (old age,
255 overweight, and presence of cardiovascular diseases) indicate a lower hazard of leaving ICU alive. Binary logistic
256 regression was used to assess whether the 28-day-mortality was significantly different between patients who
257 received high or low-dose steroids and those who received IL-6R antagonists (alone or combined). No
258 significant association was observed between the use of steroids (low-dose or high- dose) and mortality (**eTable**
259 **11-13).**
260 Unweighted and weighted Kaplan–Maier estimates were constructed to assess the association between
261 treatment with hospital and ICU LOS before and after IPTW. After IPTW, no statistically significant differences
262 were observed between the groups (p=0.52). In adjusted analysis, patients who received IL-6R antagonists
263 were more likely to experience liver dysfunction (23.9%) than those who received steroids (14.6 %) or
264 combination therapy (11.9%) (p=0.038). High troponin levels were reported in patients who received
265 combination therapy. There was no difference in the overall incidence rate of bacteremia among the three
266 groups. Linear mixed modeling and linear marginal trends were used to assess changes in the PF ratio and
267 showed that the use of IL-6R antagonists or combination therapy was not associated with significantly

268 different changes in the PF ratio as compared to the use of steroids alone. Exploratory analyses including SOFA
269 and highest FiO2 on risk adjusted mortality and VFD showed comparable finding to primary analysis. (**eTables**
270 **14-18, eFigure 1-3**).

271 **Discussion**

272 We reported the clinical characteristics and outcomes of adult ICU COVID-19 patients, required iMV,
273 and received either monotherapy with IL-6R antagonists or steroids or combination therapy within a large,
274 multinational registry. We observed no significant difference in outcomes among the three groups and among
275 those who received IL-6R antagonists compared to low-and high-dose steroids. The results of the present
276 study motivate future comparative studies between IL-6R antagonists and high-dose steroids. We consider
277 this is relevant during time of shortage in resource-limited settings, or with the huge demand for tocilizumab
278 for other indications, such as chimeric antigen receptor T-cell (CAR-T)-induced cytokine release syndrome,
279 Castleman disease, and rheumatoid arthritis. Moreover, IL6-R antagonists are expensive medications and may
280 be available at only a limited number of hospitals. We have provided insights on whether high-dose steroids
281 would act as a substitute for tocilizumab, saving thousands of dollars and preserving it for other indications.
282 Although the observational nature of our study precludes the examination of potential interactions, we
283 consider our results useful for generating hypotheses and to bridge the knowledge gap regarding different
284 steroid regimens with IL-6R antagonists.

285 IL-6R antagonists have been investigated in previous studies with conflicting results. Given the wider
286 accessibility of tocilizumab, this agent was the focus of prior trials. Randomized data available on the use of
287 tocilizumab in COVID-19 patients neither overwhelmingly support nor convincingly refute routine use [23].
288 Some trials failed to demonstrate a reduction in mortality and other trials found that tocilizumab lowered the
289 incidence or duration of ICU and hospital stays or lowered the composite rate of MV and death [24,25]. Our
290 findings are similar to the results of several RCTs which did not demonstrate all-cause mortality benefit in
291 patients receiving tocilizumab [24-28]. In contrast, the REMAP-CAP trial showed that the use of either
292 tocilizumab or sarilumab reduced both mortality and time to ICU discharge, and increased the number of

293 organ support-free days compared to no immune modulation in ICU patients requiring respiratory support
294 [9]. Moreover, a recent study published in *Chest* showed superior survival outcomes for patients treated with
295 a combination of corticosteroids and tocilizumab compared with patients treated with corticosteroids alone
296 (up to 15 mg dexamethasone) (HR, 0.66; 95% CI, 0.53,0.83; p=0.004) [29]. The reasons for these differences
297 include varying degrees of respiratory dysfunction among patients enrolled in each study, racial and ethnic
298 differences in the populations studied, corticosteroid use, inclusion of sarilumab, and differences in the use
299 of other co-interventions because the trials were conducted at different times during the pandemic as COVID-
300 19 treatment practice evolved [30]. The findings of our study may be explained by different types and doses
301 of steroids including high-dose steroids in our analysis while REMAP-CAP included fixed dose/duration
302 steroids and shock dependent hydrocortisone. In RECOVERY, there was no difference in duration of iMV or
303 VFD as only 185 patients had such ventilation successfully removed within the first 28 days [10]. Although our
304 sample size is limited and definitive conclusions cannot be made regarding the effectiveness of the different
305 therapies, further adequately powered studies are warranted to test our hypothesis.

306 The RECOVERY trial suggested that dexamethasone 6 mg IV daily resulted in a lower death rate than
307 the usual care group in patients receiving iMV [5]. After results from the RECOVERY trial became publicly
308 available, further steroid trials were stopped prematurely because the equipoise for withholding
309 corticosteroids was no longer present, and corticosteroids became the standard care for ICU patients with
310 COVID-19 requiring MV or supplemental oxygen [31-34]. On the other hand, the Italian National Institute for
311 Infectious Diseases recommends a 10-day regimen: a 5-day full dose of methylprednisolone 1 mg/kg daily or
312 dexamethasone 20 mg daily (defined as high-dose steroids in our study). This regimen is lower than the fixed
313 dexamethasone dose used in the RECOVERY trial and that described in the literature for non-COVID ARDS
314 [13,35]. Prior studies have suggested that moderate-to-high dose steroid regimens resulted in a greater
315 reduction in mortality, shorter ICU LOS, lower organ dysfunction, lesser requirement for MV or renal
316 replacement therapy, and no increase in medical or infectious complications when compared to low-dose
317 regimens in ICU COVID-19 patients [33,36].

318 Regarding the inflammatory marker, majority of the patients in our study had a baseline CRP level of
319 greater than 75 mg/L at baseline, indicating that hyperinflammatory phenotypes and high degrees of critical
320 illness, supporting the mechanism of immunomodulators. Nonetheless, recent studies have shown that
321 systemic levels of cytokines in COVID patients may not be as high as seen with sepsis and ARDS. It may be that
322 local inflammation, as evidenced by respiratory dysfunction, is a more useful indicator of which patients will
323 benefit from IL-6 inhibition [37]. Although COVID-19 treatments were not used uniformly prior to matching
324 and patients did not receive up-to-date standards of care, especially in the early pandemic phase, we utilized
325 rigorous methods to match the three groups concerning the use of anticoagulation, hydroxychloroquine,
326 antiviral (including remdesivir), and azithromycin.

327 Patient selection, timing, and dose of immunomodulator are important considerations in optimizing
328 the effectiveness. The optimal administration time may be at onset of systemic hyperinflammation from the
329 host immune response and before the onset of multi-system organ failure [38]. This is consistent with several
330 studies suggesting the lack of benefit or potential harm if tocilizumab was administered "too early" (due to
331 risk of viral replication) or "too late" [39]. The initial RCTs suggested that the maximum benefit from IL-6R
332 antagonists was seen when administered to rapidly deteriorating patients with signs of inflammation, as seen
333 in the most severely ill patients with COVID-19 with the highest death risk. In the REMAP-CAP, > 75% of the
334 participants received IL-6 inhibitors within three days of hospital admission [9]. In our study, the time of
335 steroids and IL-6R antagonists administration was in agreement with the prior findings where the majority
336 were administered in the first 48 h of ICU admission. Of note, patients who received IL-6R antagonists or
337 steroids within ICU days 0 or 1 were included for the target trial approach. Moreover, the number of
338 tocilizumab and sarilumab doses that were administered in our study were comparable to those reported in
339 the literature where the majority of the population received one dose.

340 There is concern regarding additive immunosuppression with administration of steroids and IL-6R
341 antagonists. In our study, we found no difference in the rate of superinfections between the three groups.
342 Additionally, it was unclear from our analysis whether the infection was the result of a prolonged ICU stay or

343 repeated administration of IL-6R antagonists with steroids**.** Importantly, this study reinforces the risk of liver
344 injury due to IL-6 inhibition. In the REMAP-CAP, an assessment of the safety was limited by the low number
345 of AEs. Clinicians should be aware of these effects and should weigh the risks and benefits of treatment.
346 Whether this risk is intensified with repeated administration of IL-6R antagonists or related to patients' critical
347 presentation warrant investigation in future studies.

348 The strengths of this study lie in the large number of patients, and multinational nature. Prior studies
349 were limited to two or three hospitals and restricted by geography. Our study used data from the largest
350 COVID-19 registry across the globe and represented a spectrum of intensive care with racially and ethnically
351 diverse cohorts, thereby maximizing generalizability. By including a large number of hospitals, we also
352 identified considerable variation in practice patterns that we accounted for risk-adjustments in our statistical
353 analysis. Moreover, we included patients with laboratory-confirmed COVID-19 PCR tests, thereby minimizing
354 the selection or surveillance bias at each center. Furthermore, we have strengthened the validity of our
355 analysis by using MSM, which allows for proper adjustment of time-dependent confounding variables,
356 adjustment for immortal time bias, and indication bias [20,40]. We also conducted a novel method "target
357 trial approach" to reduce the immortal bias associated with observational studies [17,22].

358 We acknowledge several limitations. First, randomized controlled trial are critical for exploring the
359 causal effect of treatments and clinical outcomes and accurately quantifying the risks. Second, our sample size
360 was limited, indicating that there were risks of type II errors. Although we used the best available method to
361 compare well-balanced groups, controlling for confounders in observational study may be incomplete despite
362 all efforts. Moreover, there was a large proportion of incomplete data for SOFA and APACHE II scores, because
363 of the heavy burden experienced by participating clinicians during the pandemic. We also did not report the
364 steroid and IL-6R antagonist administration time from symptom onset and we did not address the potential
365 role of IL-6R antagonists in preventing MV or the role of IL-6 level (available only in 24 patients of our cohort)
366 in predicting IL-6R antagonist responses, all of which are important questions that warrant further
367 investigation. In addition, the standard treatment protocol for COVID-19 evolved since the analysis of this

368 study, which may have impacted the clinical characteristics and outcomes for patients who presented in the
369 later phase of the pandemic. The steroid duration was highly variable, and data entry was inconsistent. Thus,
370 we were unable to completely minimize the effect of this important variable. We also did not have detailed
371 documentation on the AEs and we were unable to collect data on the time to viral clearance. Finally, while all
372 patients in our cohort had a minimum follow-up time of 28 days, additional follow-up may help characterize
373 the long-term sequelae, especially the incidence of invasive fungal infection, pneumocystis pneumonia, and
374 multi-drug resistance organisms. Going forward, we propose to include research findings, including ours, into
375 the VIRUS web-based decision aid to evaluating the risk, benefit, and burden of specific interventions
376 considering prior knowledge, clinical context, and preference, and also to include clinical decision support
377 tools in the future to determine how the aforementioned parameters are modified by new research findings.

378 **Conclusions**

379 In this study, we observed no significant difference in clinical outcomes between patients who received
380 monotherapy with an IL-6R antagonist or corticosteroid versus combination therapy with both. There was no
381 significant difference between patients who received IL-6R antagonists and those who received low-and high-
382 dose steroids. While observational studies cannot suggest causality, further randomized clinical trials are
383 needed to evaluate the clinical outcomes and safety of high-dose steroids to be used as substitutes during a
384 time of shortage in resource-limited settings for critically ill COVID-19 patients.

385 **Acknowledgment**

386 We thank the SCCM Discovery VIRUS data registry and the Collaborative Co-authors listed in **Supplementary**
387 **file 2** for providing and maintaining the database of hospitalized COVID-19 patients which made this study
388 possible. We are particularly grateful and thankful to Professor Yaseen M Arabi at King Saud bin Abdulaziz
389 University for Health Sciences and King Abdullah International Medical Research Center for inputs and review
390 of this manuscript. We thank the ICU physicians, nurses, respiratory therapists, physiotherapists, pharmacists
391 across the globe for their efforts to save the lives of ICU patients and their braveness in fighting the COVID-19
392 pandemic.

393

394 **Authors contribution**

395 MA: proposed the study, led the manuscript writing and did the data collection. AK: made the statistical analysis of
396 this study. All authors made substantial contributions to the concept, design, data collection, and has further
397 participated in the analysis and interpretation of the data. All authors participated revised the manuscript for
398 important intellectual content and approved the final version to be published. We confirmed that the authorship
399 followed the uniform requirements for manuscripts submitted to biomedical journals.

400 **Availability of data and material**

401 The datasets used and analyzed during the current report are available from the corresponding
402 author on reasonable request.

403 **Financial support and sponsorship:** None

404

405 **References**

406 1. Rizvi, Mahrukh S., Gallo De Moraes, Alice. New Decade, Old Debate: Blocking the Cytokine Pathways
407 in Infection-Induced Cytokine Cascade. Critical Care Explorations. 2021; 3- p e0364.
408 2. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-
409 6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents.
410 2020;55:105954.
411 3. Moore J, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473-4.
412 4. Amer M, Bawaeer M, Dahhan T, Kseibi E, Butt A, Abujazar M, et al. The current use of anti-IL6 and
413 corticosteroids in COVID-19 patients with cytokine-release syndrome. Saudi Crit Care J. 2020;4:21-4.
414 5. **RECOVERY** Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al.
415 Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.
416 6. Parr JB. Time to reassess tocilizumab's role in COVID-19 pneumonia. JAMA Intern Med. 2021;181:12-
417 5.

418 7. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label use of
419 tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020;92:1787-8.
420 8. Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory
421 Soup. N Engl J Med. 2021:NEJMe2103108.
422 9. **REMAP-CAP** Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al.
423 Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med.
424 2021;NEJMoa2100433.
425 10. **RECOVERY** Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al.
426 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a
427 randomised, controlled, open-label, platform trial. medRxiv 2021.02.11.21249258; doi:
428 https://doi.org/10.1101/2021.02.11.21249258
429 11. COVID-19 real-time learning network. IDSA treatment guideline for COVID-19.
430 https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-
431 interventions/Tocilizumab-IL-6-Inhibitors/. Accessed 17 March 2021.
432 12. NIH guideline for COVID-19. https://www.covid19treatmentguidelines.nih.gov/whats-new/.
433 Accessed 17 March 2021.
434 13. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the
435 acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med.
436 2020;8:267-76.
437 14. Walkey AJ, Kumar VK, Harhay MO, Bolesta S, Bansal V, Gajic O, et al. The Viral Infection and
438 Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related
439 Critical Illness. Crit Care Explor. 2020;2:e0113.
440 15. Walkey AJ, Sheldrick RC, Kashyap R, Kumar VK, Boman K, Bolesta S, et al. Guiding Principles for the
441 Conduct of Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and Beyond:

442 The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study
443 Registry. Crit Care Med. 2020;48:e1038-44.
444 16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening
445 the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for
446 reporting observational studies. Int J Surg Lond Engl. 2014;12:1495-9.
447 17. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for
448 assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
449 18. Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, et al. Outcomes of Patients with
450 Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and
451 Respiratory Illness Universal Study Registry. Crit Care Med. 2021;49:437-48
452 19. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in
453 critical care research. Am J Respir Crit Care Med. 2019;200:828-36.
454 20. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology.
455 Epidemiology. 2000;11:550-60
456 21. Almirall D, Griffin BA, McCaffrey DF, Ramchand R, Yuen RA, Murphy SA. Time-varying effect
457 moderation using the structural nested mean model: estimation using inverse-weighted regression
458 with residuals. Stat Med. 2014;33:3466-87.
459 22. Vail EA, Gershengorn HB, Wunsch H, Walkey AJ. Attention to Immortal Time Bias in Critical Care
460 Research. Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202008-3238CP. Epub ahead
461 of print
462 23. McCreary E K, Meyer N J. Covid-19 controversies: the tocilizumab chapter. BMJ. 2021;372:n244.
463 24. Rosas IO, Bräu N, Waters M, et al [**COVACTA** trial investigators]. Tocilizumab in hospitalized patients
464 with severe Covid-19 pneumonia. N Engl J Med.DOI: 10.1056/NEJMoa2028700.
465 25. Salama C, Han J, Yau L, et al [**EMPACTA** trial investigators]. Tocilizumab in patients hospitalized with
466 Covid-19 pneumonia. N Engl J Med 2021;384:20-30

467 26. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. **BACC Bay**
468 Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl
469 J Med. 2020;383:2333-44.
470 27. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. **CORIMUNO-19**
471 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and
472 Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:32-40.
473 28. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. **RCT-TCZ-COVID-19** Study Group.
474 Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19
475 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:24-31.
476 29. Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, et al. Northwell COVID-19 Research
477 Consortium. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease
478 2019 Cytokine Storm. Chest. 2021;159:933-48.
479 30. Villar J, Confalonieri M, Pastores SM, Meduri GU. Rationale for Prolonged Corticosteroid Treatment in
480 the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. Crit Care Explor.
481 2020;2:e0111.
482 31. WHO Rapid Evidence Appraisal for COVID-19 Therapies (**REACT**) Working Group, Sterne JAC, Murthy
483 S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids
484 and mortality among critically ill patients with COVID-19: a metaanalysis. JAMA. 2020;324:1330-41.
485 32. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality
486 and organ support in patients with severe COVID-19: the **REMAP-CAP COVID-19 corticosteroid**
487 **domain** randomized clinical trial. JAMA. 2020;324:1317-29.
488 33. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone
489 on days alive and ventilator-free in patients with moderate or severe acute respiratory distress
490 syndrome and COVID-19: the **CoDEX** randomized clinical trial. JAMA. 2020;324:1307-16.

491 34. Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J, et al. Effect of hydrocortisone on 21-
492 day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical
493 trial. JAMA. 2020;324:1298-306.
494 35. Nicastri E, Petrosillo N, Ascoli Bartoli T, et al. National institute for the infectious diseases "L.
495 Spallanzani", IRCCS recommendations for COVID-19 clinical management. Infect Dis Rep.
496 2020;12(1):8543.
497 36. Monedero P, Gea A, Castro P, Candela-Toha AM, Hernández-Sanz ML, Arruti E, et al. Early
498 corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort
499 study. Crit Care. 2021;25:2
500 37. Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome
501 in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med 2020; 8:
502 1209-18.
503 38. Siddiqi HK, Mandeep MR. COVID-19 illness in native and immunosuppressed states: A clinical-
504 therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-7.
505 39. Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 induced cytokine release syndrome
506 a cautionary case report. Chest. 2020;158:e15-9.
507 40. Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, et al. Efficacy and safety of tocilizumab
508 in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:215-
509 27.



Figure 1. Flow chart for data extraction from VIRUS database

Abbreviation: iMV: invasive mechanical ventilation, DNR: Do-not-resuscitate order

Table 1. Baseline characteristics after adjustments for baseline covariates

	Steroids	IL6-R antagonists	Both	P	SMD
N ¶	811.6	596.8	698.9		
Male	528 (65.1)	430 (72.1)	433 (62)	0.249	0.145
Age (mean (SD))	60.9 (14.2)	60.6 (13.8)	61.5 (12.8)	0.9	0.042
Weight at admission (mean (SD))	91.3 (27.9)	92.7 (26.3)	94.5 (29.9)	0.622	0.076
Ethnic group				0.934	0.113
Hispanic	163 (20.1)	128 (21.5)	147 (21.3)		
Non-Hispanic	385 (47.4)	285 (47.8)	325 (47)		
CVD	176 (21.6)	75 (12.6)	161 (23)	0.108	0.183
Asthma/COPD	143 (17.6)	84 (14.1)	147 (21)	0.326	0.121
Hydroxychloroquine	164 (20.2)	181 (30.2)	180 (26)	0.150	0.141
Azithromycin	300 (37)	279 (46.7)	294 (42.1)	0.324	0.122
Antiviral	145 (18)	78 (13.1)	141 (20.2)	0.423	0.136
ARDS grade				0.794	0.148
No	542 (66.8)	441 (74)	489 (70)		
Mild (P:F 200-300)	22 (2.8)	17 (3)	23 (3.3)		
Moderate (P:F 100-199)	83 (10.7)	38 (6.5)	41 (6)		
Severe (P:F< 100)	132 (16.9)	79 (13.8)	113 (16.2)		
Any Anticoagulant	693 (85.3)	504 (84.4)	560 (80.1)	0.456	0.093
Therapeutic anticoagulation	179 (22.1)	87 (14.6)	162 (23.1)	0.151	0.147
FiO2 lowest (mean (SD))	0.56 (0.25)	0.52 (0.24)	0.57 (0.24)	0.434	0.127
Neuromuscular blocker	659 (82)	520 (87)	625 (89.4)	0.151	0.16
Vasopressors	638 (78.6)	506 (84.8)	612 (87.5)	0.139	0.16

Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation

¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals.

Abbreviation: ARDS: Acute respiratory distress syndrome ; CVD : cardiovascular diseases, COPD: Chronic obstructive pulmonary disease ; IPTW: Inverse probability weighting, SMD: standardized mean difference; SD: standard deviation; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

Table 2: Utilization pattern of steroids and IL6-R antagonists in relation to ICU admission

	Value
Average daily dose (mg dexamethasone equivalent) [#]	7.50 [6;14.1]
Low steroid dose	496 (80.8)
High steroid dose [†]	118 (19.2)
Date of steroid start in relation to ICU admission [*]	
0	384 (55.6)
1	102 (14.8)
2	37 (5.4)
3	22 (3.2)
4	24 (3.5)
After day 5	118 (17)
Tocilizumab	213 (78.3)
Tocilizumab number of doses [¶]	
1	180 (84.5)
2	28 (13.1)
3	5 (2.3)
Sarilumab	59 (21.7)
Sarilumab number of doses [¶]	
1	50 (84.7)
2	6 (10)
>2	3 (5.1)
Date of IL6-R antagonists start in relation to ICU	
0	129 (39.5)
1	55 (20.3)
2	30 (11.1)
3	21 (7.8)
4	4 (1.5)
After day 5	32 (11.8)

[#] The dose was available to 614 patients

[†] High dose was defined as > 15 mg/day of dexamethasone or dexamethasone equivalent

[*] % The proportion was calculated from the number of patients who received the steroids (n = 693).

[¶] % was calculated from patients who received IL6-R antagonists (n=272)

The average daily dose of steroids was calculated by averaging the daily doses received by the patients during the ICU stay.

Figure 2 . Association between treatment modality, VFD, and 28-day mortality

Panel A.

Modality	aIRR (95% CI)	P
Steroids	Ref	
IL6-R antagonist		
VFD (IPTW)	1.12 (0.88;1.4)	0.4
VFD (IPTW- Highest FiO2)	1.13 (0.9;1.42)	0.3
VFD (IPTW-SOFA)	1.12 (0.89;1.4)	0.4
Sensitivity analysis (Target trial)	1.13 (0.87;1.45)	0.4
Combined		
VFD (IPTW)	0.83 (0.6;1.14)	0.2
VFD (IPTW- Highest FiO2)	0.88 (0.64;1.2)	0.4
VFD (IPTW-SOFA)	0.77 (0.56;1.06)	0.1
Sensitivity analysis (Target trial)	0.64 (0.34;1.23)	0.2



Panel B

Modality	N	aOR (95% CI)	P
Steroids	583	Ref	
IL6-R antagonist			
28-day mortality (IPTW)	168	0.68 (0.44;1.07)	0.1
Hospital morality (IPTW)	170	0.68 (0.43;1.09)	0.1
28-day mortality (IPTW-SOFA)	170	0.7 (0.45;1.08)	0.1
Sensitivity analysis (Target trial)	121	0.6 (0.35;1.03)	0.06
Combined			
28-day mortality (IPTW)	104	1.07 (0.67;1.7)	0.8
Hospital morality (IPTW)	101	1.23 (0.72;2.11)	0.5
28-day mortality (IPTW-SOFA)	101	1.21 (0.76;1.93)	0.4
Sensitivity analysis (Target trial)	35	1.96 (0.9;4.28)	0.09



Panel A. Association between treatment modality and ventilator-free days
Panel B. Association between treatment modality and 28-day mortality
Estimates in panel A represent adjusted incident rate ratio (aIRR) . Estimates in panel B represent adjusted odds ratio (aOR)
Missing data outcomes in sensitivity analysis to emulate a target trial: 4 patients missing 28-day mortality status and 15 missing duration of Imv

Abbreviation: VFD ventilation free days, IPTW: Inverse probability of treatment weight, IPTW-SOFA: Inverse probability weighting with added Sequential Organ Failure Assessment (SOFA), IPTW-Highest FiO2: Inverse probability weighting with added fractional inspired oxygen concentration

- Marginal structural models (MSM) was used to adjust for time-dependent confounders. Observations were weighted by the inverse probability of treatment weight (IPTW).
- In sensitivity analysis to emulate a target trial: eligible patients on MV were included if they received IL-6R antagonists or steroids within ICU days 0 or 1. Patients who died within the first 48 hours were also excluded.

Table3 . Linear regression analysis for ventilation-free days after adjusting for covariates stratified by steroid dose

Predictors	*ß*	*CI*	*p*
Group			
IL-6 antagonist	*Reference*		
Steroid Low-dose	0.62	-1.54 – 2.78	0.573
Steroid High-dose	-1.19	-3.85 – 1.47	0.379
Age	-0.01	-0.07 – 0.04	0.598
Weight	-0.02	-0.05 – 0.00	0.072
Lowest FiO2	3.20	1.26 – 8.27	**0.015**
Gender			
Female	*Reference*		
Male	-1.09	-2.58 – 0.40	0.153
Neuromuscular blocker			
Yes	*Reference*		
No	2.87	0.18 – 5.55	**0.036**
Vasopressors			
Yes	*Reference*		
No	-1.69	-4.17 – 0.79	0.181
Therapeutic anticoagulation			
No	*Reference*		
Yes	2.02	0.26 – 3.78	**0.025**
Any anticoagulation			
Yes	*Reference*		
No	-1.36	-3.45 – 0.73	0.202
Ethnicity			
Hispanic	*Reference*		
Non-Hispanic	0.67	-1.20 – 2.54	0.479
Hydroxychloroquine			
Yes	*Reference*		
No	1.36	-0.57 – 3.30	0.167
Antivirals			
Yes	*Reference*		
No	0.04	-1.87 – 1.95	0.965
Azithromycin			
Yes	*Reference*		
No	-0.28	-1.85 – 1.30	0.729
ARDS grade			
No	*Reference*		
Mild (P:F 200-300)	-3.47	-7.78 – 0.84	0.114
Moderate (P:F 100-199)	-1.27	-3.96 – 1.41	0.353
Severe (P:F< 100)	-1.63	-3.88 – 0.62	0.156
CVD			
No	*Reference*		
Yes	-0.97	-2.79 – 0.85	0.296
Asthma/COPD			

No	*Reference*		
Yes	0.40	-1.45 – 2.25	0.670

The normality of residuals were inspected to ensure good model fit for the linear regression model.

ß is the log of incident rate ratio. if 0 then it is not significant

Figure 3. Adjusted survival curves for competing risk models for (A) mortality (B) discharge



Risk regression models for survival endpoints in the presence of competing risks were fitted using binomial regression based on a time sequence of binary event status variables. The same predictors used for marginal structured model were used in the cause-specific Cox regression analysis

Supplementary Appendix

e Table 1 Included hospitals

e Table 2. Definitions of selected variables and clinical outcomes

e File 1. Additional details for statistical analysis

e Table 3. Distribution of baseline covariates across groups before matching

e Table 4. Other baseline characteristics of the total cohort

e Table 5. Ventilator and radiology characteristics of the included patients at days 0 and 1 of ICU stay

e Table 6. SOFA and APCHE-II scores at baseline

e Table 7. ICU support and interventions at days 0 of ICU admission after IPTW and matching

e Table 8. Distribution of Anakinra and Remdesivir doses

e Table 9. Laboratory parameters at ICU day 0 [unadjusted]

e Table 10. Laboratory parameters at ICU day 0 after adjustment of covariates

e Table 11. Primary outcomes before matching

e Table 12. Cox-proportional hazard model for ICU discharge

e Table 13. Association between medication use and mortality after adjustment stratified by steroid dose

e Figure 1. Unweighted and weighted Kaplan–Maier estimates for association between treatment and ICU LOS

e Figure 2. Unweighted and weighted Kaplan–Maier estimates for association between treatment hospital LOS

e Table 14. Documented complication during hospitalization after adjusting for baseline covariates

e Table 15. Causative microbiology and rate of secondary infections across the groups

e Table 16. Linear mixed modeling of PF ratio

e Figure 3. Estimated marginal trend for the change in PF ratio across groups.

e Table 17. Change in lab values

e Table 18. Need for inotropes

e File 2. Collaborative Co-Author List.

Supplemental Table 1 Included Hospitals

Country	**N**
1. United States	60
2. Japan	4
3. Saudi Arabia	4
4. India	2
5. Belgium	2
6. Colombia	1
7. Mexico	1
8. Bosnia and Herzegovina	1
9. Croatia	1
10. Egypt	1
11. Hungary	1
12. Hondurus	1
13. Russia	1
14. Serbia	2
15. Spain	1
16. Pakistan	1
Total	84

These are the included hospital per country in the VIRUS registry

Supplementary Table 2. Definitions of Selected Variables and Clinical Outcomes

Severity of illness was evaluated using Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHEII) scores.	The worst value for baseline laboratory tests was chosen. These data were collected within the first 24 h after admission to the ICU. If that data were not available, then data closest to admission were recorded.
Duration of mechanical ventilation	Recorded as the number of calendar days from intubation to extubation or until ICU discharge, or death whichever occurs first. The median ventilator-free days was calculated as calendar days with no ventilator support to day 28. Participants who die before day 28 are assigned zero free days.
Secondary infections	Identified based on positive blood, urine, and sputum cultures. Only infections occurring after administration of anti-IL6 or steroids were considered. The definition of infection outcomes was following VIRUS Standard operating definitions
28-day mortality	Defined as the time from hospital admission until death within 28 days, with censoring of alive patients at 28 days.
Acute respiratory distress syndrome (ARDS)	Classified according to the Berlin definition [1]. The PF ratio was calculated by dividing the arterial Po2 by the FiO2 at the same time. If the FiO2 was not available, the lowest FiO2 was used followed by the highest FiO2.
Critical COVID-19	Defined by the WHO criteria for ARDS, sepsis, septic shock or other conditions that would normally require the provision of life-sustaining therapies, such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy [2].
ICU and hospital length of stay	the interval between the ICU or hospital admission date to the ICU or hospital discharge date was calculated in days

References :

(1) ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. PMID: 22797452

(2) Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, Arabi YM et al A. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med. 2021 Mar 1;49(3):e219-e234. doi: 10.1097/CCM.0000000000004899

Supplementary file 1. Additional details for statistical analysis

International System of Units (SI) were used to represent laboratory data unless otherwise specified. The data were checked for integrity and outliers in the laboratory data (numbers > the 99th percentile) were removed based on clinical judgment and whether the extreme values were clinically plausible.

Marginal structural modeling (MSM): allows for proper adjustment of time-dependent confounding variables, adjustment for immortal time bias and indication bias. Immortal time bias refers to the requirement that patients survive long enough to receive the intervention of interest, leading to a potential incorrect overestimation of a positive treatment effect. Indication bias from time-varying confounding variables refers to having an association related to the indication of the intervention that evolves throughout the course of an illness.

MSM using propensity scores were used to compare the primary and secondary outcomes between the three regimens after adjusting for non-time and time-varying covariates [1]. All patients had baseline data on ICU admission. However, the follow-up time varied between patients. Moreover, some variables, such as therapeutic anticoagulation, varied daily. MSMs were used to adjust for variability between patients who received the three regimens. Thus, handling time-varying covariates when weighing observations may have the following limitations: 1. the longitudinal outcome and time-varying covariate may not be available at the same time points: 2. the longitudinal outcome at a particular time point, t, may depend not only on the value of the covariate at the same time point but also at those at other time points. Thus, weighted regressions may be used to account for time-varying confounders using MSMs.

For dichotomous outcomes, the corresponding mixed effects model, namely a mixed effects logistic regression gives fixed effects coefficients that have an interpretation conditional on the random effects. Most often, this is not the interpretation we want. The GEE approach does give coefficients with a marginal / population-averaged interpretation.

However, an additional practical point that also need to consider is missing data and almost always we have to deal with incomplete data. With regard to this point, mixed models give valid results under the less stringent missing at random assumption compared to the (standard not weighted) GEE that give valid results under the less realistic missing completely at random assumption.

Taking both points (i.e., interpretation and missing data) into account, would most often like to fit a mixed model to be more protected for the missing data but want to obtain parameters that have a population averaged interpretation. An early solution towards this direction was the marginalized mixed models proposed by Heagerty, but, in general, these are computationally intensive to fit. A more recent approach that seems to solve the problem

has been proposed by Hedeker et al. This is implemented in the function marginal_coefs() of the R package GLMMadaptive.

The fixed effects estimates in mixed models with nonlinear link functions have an interpretation conditional on the random effects. However, often we wish to obtain parameters with a marginal / population averaged interpretation, which leads many researchers to use generalized estimating equations, and dealing with potential issues with missing data. Nonetheless, recently Hedeker et al. have proposed a nice solution to this problem. Their approach is implemented in function marginal_coefs(). For example, for model fm we obtain the marginalized coefficients.

The function calculates the marginal log odds ratios in our case (because we have a binary outcome) using a Monte Carlo procedure with number of samples determined by the M argument. Standard errors for the marginalized coefficients are obtained by setting std_errors = TRUE in the call to marginal_coefs(), and require a double Monte Carlo procedure for which argument K comes also into play.

Generalized estimating equations (GEE) were constructed to evaluate the impact of the treatment (t) on the outcome (d) and to handle the time-varying covariate (v) in the panel dataset. Since the outcome was a continuous variable, a generalized linear Gaussian family with identity link was used. Auto-regressive (AR1) correlation structure was selected since this was a time series (panel) data; we expected the correlation to decay as the outcome values were farther away from the time of interest.

Covariates included in the model were age, sex, ethnicity, asthma/COPD, ARDS grade (none, mild, moderate or severe) at admission, respiratory failure at admission, history of CVD (diabetes, hypertension, coronary heart diseases or congestive heart failure), and the baseline lowest arterial oxygen concentration. Other covariates included the use of any anticoagulation, therapeutic anticoagulation, hydroxychloroquine, azithromycin, and antivirals. The effect of adding steroids, IL-6 antagonists was assessed by including each variables as a dummy coded variable in the marginal model. In addition, an interaction term was added to the model to assess whether the combination of both drugs was associated with a statistically significant effect size.

inverse probability weighting (IPTW) are weights assigned to each observation across time conditioned on the previous exposure history, which are then multiplied to generate a single weight for a subject. Similar to conventional propensity score estimation, IPTW is generated using either a logit or probit model that regresses covariates to a treatment group (exposure) variable. With IPTW, the previous exposure history is incorporated to the propensity score estimation, which is time-varying. Standardized weights in a longitudinal setting are estimated. The numerator contains the probability of the observed exposure at each time point conditioned on the observed exposure history of the previous time point and the observed non-time varying covariates. The denominator contains the probability of the observed exposure at each time point conditioned on the observed exposure history of the previous time point, the observed time-varying covariates history at the current time point, and the non-time varying covariates. In standardized weights, the time-varying confounders are captured in the

denominator but not in the numerator. However, the non-time varying (also known as fixed-time) covariates are captured in both the numerator. Due to the longitudinal nature of the data, the GLMMadaptive package was used for model fitting. The Package GLMMadaptive provides a suit of functions for fitting and post-processing mixed effects models for grouped/clustered outcomes which have a distribution other than a normal distribution. In particular, let yi denote a vector of grouped/clustered outcome for the i-th sample unit (i=1,…,n).

Standardized mean difference (SMD) were reported for comparison between cohorts before and after matching

Handling of missing data:

The generalized boosted model (GMB) creates a separate level during matching called NA and creates weights based on the distribution of missing values. So basically it considers NA as a level of its own. The weights are created for all respondents and are taking the missing values into consideration. Imputation requires that data is missing at random which is not the case here. Moreover, the variables we used had few missing values so there is no problem which would not have been the case if we used the SOFA and APACHE which had a lot of missing data.

The pseudo population

The populations are weighed by the probability of receiving treatments based on other confounders. The weights were produced using generalized boosted models and these weights were used when doing further analysis. The pseudo population is the sum of weights for each group rather than considering each observation as 1. Thus, the numbers can increase or decrease compared to the initial number of the group depends on the assigned weights. The aim to emulate randomized trial to create a pseudo study cohort, where the weighted version can balance off the covariate bias and mimic a randomized treatment assignment situation

References : (1) Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-60.

Supplementary Table 3. Distribution of baseline covariates across groups before adjustment

	Steroids	IL6-R antagonists	Both	P
	N=589	N=170	N=101	
Sex				0.387
Female	205 (34.8)	49 (28.8)	34 (33.7)	
Male	384 (65.2)	119 (70)	70 (66.3)	
Age, mean (SD)	61.1 (14.3)	57.4 (14.7)	62.1 (13.2)	0.006
Therapeutic anticoagulation				0.238
No	455 (77.2)	136 (80)	75 (74.3)	
Yes	134 (22.8)	32 (20)	29 (25.7)	
Ethnic group				<0.001
Hispanic	112 (19)	48 (28.2)	22 (21.7)	
Non-Hispanic	263 (44.7)	80 (47.1)	55 (54.4)	
Weight (kg) at Hospital Admission, mean (SD)	90.1 (27.7)	96.9 (28)	95.3 (28.5)	0.012
Cardiovascular disease	130 (22.1)	16 (9.4)	23 (22.7)	0.001
Asthma/COPD	102 (17.3)	19 (11.1)	29 (28.7)	0.002
Hydroxychloroquine	87 (14.8)	87 (51.2)	41 (40.6)	<0.001
Antiviral	474 (80.5)	159 (93.5)	86 (85.1)	<0.001
Azithromycin	204 (34.6)	93 (54.7)	50 (49.5)	<0.001
ARDS				.
No	380 (67.3)	144 (84.7)	67 (66.3)	
Mild (P:F 200-300)	15 (2.7)	4 (2.4)	6 (5.9)	
Moderate (P:F 100-199)	65 (11.5)	4 (2.4)	8 (7.9)	
Severe (P:F< 100)	105 (18.6)	12 (7.1)	16 (15.8)	
Lowest FiO2, mean (SD)	0.57 (0.3)	0.51 (0.3)	0.55 (0.2)	0.123

Data presented as n (%) unless otherwise specified

Abbreviation: ARDS: Acute respiratory distress syndrome ; COPD: Chronic obstructive pulmonary disease SD: standard deviation; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

Supplementary Table 4. Other Baseline characteristics of the total cohort

	Steroids N=589	IL6-R antagonists N=170	Both N=101	P	N
Hospital Admission Source				<0.001	858
Home	207 (35.3)	42 (24.7)	36 (35.6)		
Hospital ED	177 (30.2)	92 (54.1)	43 (42.6)		
Nursing Home	25 (4.26)	2 (1.2)	2 (1.9)		
Other	5 (0.85)	1 (0.6)	0 (0)		
Outside ED	30 (5.11)	8 (4.7)	3 (2.9)		
Transfer from other Facility	143 (24.4)	25 (14.7)	17 (16.8)		
Signs and symptoms				0.803	860
Abdominal pain	38 (6.5)	5 (2.9)	7 (6.9)	0.199	860
Ageusia (loss of taste sense)	25 (4.24)	5 (2.9)	3 (2.9)	0.821	860
Loss of appetite	51 (8.7)	25 (14.7)	13 (12.9)	0.050	860
Anosmia (loss of smell sense)	19 (3.2)	4 (2.4)	6 (5.9)	0.269	860
Arthralgia	11 (1.9)	4 (2.4)	6 (5.9)	0.054	860
Chest pain/tightness	67 (11.4)	16 (9.4)	11 (10.9)	0.770	860
Chills/rigors	84 (14.3)	33 (19.4)	15 (14.9)	0.257	860
Confusion/delirium	49 (8.3)	11 (6.5)	7 (6.9)	0.689	860
Conjunctival congestion	1 (0.17)	1 (0.59)	0 (0)	0.531	860
Dry cough	283 (48)	101 (59.4)	58 (57.4)	0.014	860
Cough with sputum	69 (11.7)	25 (14.7)	16 (15.8)	0.365	860
Diarrhea	78 (13.2)	44 (25.9)	21 (20.8)	**<0.001**	860
Dizziness/lightheadedness	31 (5.3)	8 (4.7)	5 (4.9)	0.956	860
Dyspnea/shortness of breath	436 (74)	133 (78.2)	73 (72.3)	0.454	860
Fever	370 (62.8)	125 (73.5)	72 (71.3)	**0.017**	860
Headache	60 (10.2)	23 (13.5)	11 (10.9)	0.469	860
Hemoptysis	7 (1.2)	0 (0)	0 (0)	0.394	860
Malaise	91 (15.4)	28 (16.5)	23 (22.8)	0.187	860
Myalgia or fatigue	439 (74.5)	101 (59.4)	62 (61.4)	**<0.001**	860
Nasal congestion/rhinorrhea	25 (4.2)	12 (7.06)	10 (9.9)	**0.041**	860
Nausea and Vomiting	81 (13.8)	22 (12.9)	15 (14.9)	0.906	860
Night sweat	9 (1.5)	1 (0.59)	2 (1.9)	0.602	860
Seizure	6 (1.02)	1 (0.59)	0 (0)	0.852	860
Sneezing	1 (0.2)	1 (0.59)	0 (0)	0.531	860
Sore throat or throat pain	33 (5.6)	15 (8.8)	11 (10.9)	0.080	860
Swollen neck/glands (lymphadenopathy)	1 (0.2)	0 (0)	0 (0)	1.000	860
Comorbidities					
Coronary heart diseases	492 (83.5)	161 (94.7)	85 (84.2)	**0.001**	860
Hypertension	251 (42.6)	67 (39.4)	45 (44.6)	0.666	860
Cardiac arrhythmias	50 (8.5)	5 (2.9)	4 (3.9)	**0.020**	860
Congestive heart failure	72 (12.2)	10 (5.9)	9 (8.9)	**0.051**	860
Valvular heart disease	17 (2.9)	1 (0.6)	1 (0.9)	0.178	860
Chronic pulmonary disease not asthma	59 (10)	7 (4.1)	16 (15.8)	**0.005**	860
Asthma physician diagnosed	45 (7.6)	12 (7.1)	12 (11.9)	0.306	860

	Steroids N=589	IL6-R antagonists N=170	Both N=101	P	N
Pulmonary circulation disorder	7 (1.2)	1 (0.6)	2 (1.9)	0.545	860
Chronic kidney disease	58 (9.9)	14 (8.24)	12 (11.9)	0.616	860
Chronic dialysis	12 (2.04)	2 (1.18)	3 (2.9)	0.591	860
Diabetes	362 (61.5)	111 (65.3)	55 (54.5)	0.208	860
Hypothyroidism	45 (7.6)	6 (3.5)	5 (4.9)	0.127	860
Liver disease	20 (3.4)	2 (1.2)	2 (1.9)	0.319	860
Hepatitis B	2 (0.34)	1 (0.6)	0 (0)	0.679	860
Hepatitis C	11 (1.9)	3 (1.8)	2 (1.9)	1.000	860
peptic ulcer disease excluding bleeding	6 (1.02)	3 (1.8)	2 (1.9)	0.444	860
solid tumor without metastasis	26 (4.4)	0 (0)	8 (7.9)	**0.001**	860
hematologic malignancy	7 (1.2)	4 (2.4)	1 (0.9)	0.428	860
metastatic cancer	10 (1.7)	0 (0)	0 (0)	0.117	860
history of solid organ or bone marrow	1 (0.17)	0 (0)	2 (1.9)	0.059	860
HIV aids or other immunosuppression	6 (1.02)	4 (2.4)	2 (1.9)	0.238	860
stroke or other neurological disorders	47 (7.9)	4 (2.4)	5 (4.9)	**0.026**	860
Paralysis	5 (0.9)	1 (0.6)	0 (0)	1.000	860
Rheumatoid arthritis collagen vascular disease	9 (1.5)	3 (1.8)	1 (0.9)	0.910	860
Blood loss anemia	0 (0)	1 (0.6)	0 (0)	0.315	860
Iron deficiency anemia	13 (2.2)	3 (1.8)	2 (1.9)	1.000	860
Coagulopathy	4 (0.68)	3 (1.8)	1 (0.9)	0.322	860
Malnutrition	1 (0.17)	0 (0)	1 (0.9)	0.260	860
Obesity	117 (19.9)	60 (35.3)	32 (31.7)	**<0.001**	860
Substance use disorder	15 (2.6)	2 (1.2)	2 (1.9)	0.627	860
Depression	37 (6.3)	5 (2.9)	10 (9.9)	0.061	860
Psychosis	5 (0.9)	1 (0.6)	0 (0)	1.000	860
Dementia	18 (3.1)	3 (1.8)	2 (1.9)	0.757	860
Obstructive sleep apnea	33 (5.6)	19 (11.2)	11 (10.9)	**0.017**	860
Venous thromboembolism	15 (2.6)	4 (2.4)	6 (5.9)	0.192	860
Dyslipidemia hyperlipidemia	59 (10)	6 (3.5)	10 (9.9)	**0.028**	860
Admission Diagnosis/Complications					
Acute Liver Injury	22 (3.7)	5 (2.9)	6 (5.9)	0.416	860
Acute Myocardial Infarction	9 (1.5)	1 (0.6)	0 (0)	0.410	860
Acute Renal Failure Requiring Hemofiltration	23 (3.9)	5 (2.9)	8 (7.9)	0.124	860
Acute Renal Injury	89 (15.1)	31 (18.2)	14 (13.9)	0.539	860
ARDS (acute respiratory distress syndrome)	209 (35.5)	25 (14.7)	37 (36.6)	**<0.001**	860
Bacteremia	16 (2.7)	4 (2.4)	0 (0)	0.289	860
Bacterial Pneumonia	59 (10)	23 (13.5)	8 (7.9)	0.283	860
Cardiac Arrest	19 (3.2)	1 (0.6)	1 (0.9)	0.099	860
Cardiac Arrhythmia: Atrial Fibrillation	10 (1.7)	3 (1.8)	4 (3.9)	0.350	860
Cardiac Arrhythmia: Heart Block	2 (0.3)	0 (0)	1 (0.9)	0.401	860
Cardiac Arrhythmia: Ventricular Tachycardia	8 (1.4)	0 (0)	2 (1.9)	0.199	860
Congestive Heart Failure / Cardiomyopathy	13 (2.2)	1 (0.6)	3 (2.9)	0.305	860
Diabetic Ketoacidosis (DKA)	2 (0.34)	0 (0)	0 (0)	1.000	860

	Steroids N=589	IL6-R antagonists N=170	Both N=101	P	N
Delirium / Encephalopathy	48 (8.2)	4 (2.4)	3 (2.9)	**0.008**	860
Gastrointestinal Hemorrhage	2 (0.3)	1 (0.6)	1 (0.9)	0.375	860
Hyperglycemia	67 (11.4)	22 (12.9)	14 (13.9)	0.707	860
Hypoglycemia	5 (0.9)	0 (0)	0 (0)	0.632	860
Meningitis/Encephalitis	3 (0.5)	0 (0)	0 (0)	1.000	860
Myocarditis	3 (0.5)	0 (0)	1 (0.9)	0.526	860
Pneumothorax	3 (0.5)	0 (0)	2 (1.9)	0.162	860
Pleural Effusion	6 (1.02)	0 (0)	1 (0.9)	0.479	860
Rhabdomyolysis / Myositis	8 (1.4)	0 (0)	2 (1.9)	0.199	860
Seizure	5 (0.9)	0 (0)	0 (0)	0.632	860
Shock	72 (12.2)	9 (5.3)	9 (8.9)	**0.029**	860
Stroke	8 (1.4)	0 (0)	0 (0)	0.216	860
Pre-Hospital (Home) Medication					
Angiotensin-converting-enzyme Inhibitor	97 (16.5)	31 (18.2)	20 (19.8)	0.661	860
Angiotensin receptor blocker	68 (11.5)	22 (12.9)	13 (12.9)	0.848	860
Antiretroviral	2 (0.3)	2 (1.2)	1 (0.9)	0.227	860
Antibiotics	54 (9.2)	11 (6.5)	7 (6.9)	0.458	860
Anti-Diabetic	44 (7.5)	5 (2.9)	13 (12.9)	**0.009**	860
Aspirin	122 (20.7)	31 (18.2)	29 (28.7)	0.111	860
Chemotherapy currently or in the last 3	12 (2.04)	1 (0.6)	2 (1.9)	0.511	860
Immunotherapy	9 (1.5)	0 (0)	3 (2.9)	0.105	860
Inhaled corticosteroids	54 (9.2)	13 (7.7)	13 (12.9)	0.352	860
NSAID/Ibuprofen	49 (8.3)	18 (10.6)	10 (9.9)	0.619	860
Other anti-hypertensive agent (eg., beta blocker, calcium channel blocker, diuretic)	211 (35.8)	57 (33.5)	37 (36.6)	0.830	860
Paracetamol/Acetaminophen	81 (13.8)	25 (14.7)	22 (21.8)	0.111	860
Proton Pump Inhibitors	76 (12.9)	27 (15.9)	20 (19.8)	0.151	860
Statins	166 (28.2)	58 (34.1)	31 (30.7)	0.319	860
Anticoagulants	46 (7.8)	9 (5.3)	10 (9.9)	0.351	860
Hydroxychloroquine (Plaquenil)	5 (0.9)	2 (1.2)	1 (0.9)	0.865	860
Social History					
Social history (current smoker)	29 (4.9)	7 (4.12)	6 (5.94)	0.803	860
Social history (former smoker)	119 (20.2)	29 (17.1)	25 (24.8)	0.310	860
Social history (vaping)	0 (0)	1 (0.59)	0 (0.00)	0.315	860
Social history (alcohol use disorder)	26 (4.4)	6 (3.53)	5 (4.95)	0.810	860
Social history (substance use disorder)	14 (2.4)	3 (1.76)	1 (0.99)	0.812	860
Social history (unknown/not available)	37 (6.3)	5 (2.94)	4 (3.96)	0.188	860
Packs per day (PPD) patient smokes				0.099	49
< ½ PPD (0.5 PPD)	8 (21.1)	0 (0)	2 (33.3)		
1 PPD	6 (15.8)	0 (0)	2 (33.3)		
1½ PPD (1.5 PPD)	1 (2.6)	0 (0)	0 (0)		
2 PPD	4 (10.5)	1 (20)	2 (33.3)		
Unknown/Not Available	19 (50)	4 (80)	0 (0)		

	Steroids N=589	IL6-R antagonists N=170	Both N=101	P	N
Does/Did patient uses other tobacco products regularly? (Cigars)	6 (1.02)	0 (0)	1 (0.9)	0.479	860
Does/Did patient uses other tobacco products regularly? (Pipes)	1 (0.2)	0 (0)	1 (0.9)	0.260	860
Does/Did patient uses other tobacco products regularly? (Chewing tobacco)	2 (0.3)	0 (0)	0 (0)	1.000	860
Does/Did patient uses other tobacco products regularly? (No other tobacco)	9 (1.5)	1 (0.6)	3 (2.9)	0.270	860
Does/Did patient uses other tobacco products regularly? (Unknown/ Not available)	19 (3.2)	4 (2.4)	2 (1.9)	0.857	860
ARDS Type				0.114	236
Mild (P:F 200-300)	15 (8.1)	4 (19)	6 (20)		
Moderate (P:F 100-199)	66 (35.7)	4 (19)	8 (26.7)		
Severe (P:F< 100)	104 (56.2)	13 (61.9)	16 (53.3)		
Type of Shock				0.486	80
Cardiogenic shock	5 (7.6)	0 (0)	0 (0)		
Distributive shock	59 (89.4)	5 (83.3)	8 (100)		
Hypovolemic shock	2 (3.03)	1 (16.7)	0 (0)		

Data presented as n (%) unless otherwise specified

Abbreviation: ARDS: Acute respiratory distress syndrome ; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

Supplementary Table 5. Ventilator and Radiology Characteristics of the included patients at days 0 and 1 of ICU stay

	Day 0				Day 1			
	Steroids	IL6-R antagonists	combination	P	Steroids	IL6-R antagonists	combination	P
	N=589	*N=170*	*N=101*		*N=568*	*N=170*	*N=94*	
Performed diagnostics								
None	31 (5.3)	7 (4.1)	7 (6.9)	0.602	232 (40.8)	49 (28.8)	33 (35.1)	**0.015**
Chest X-ray	467 (79.3)	149 (87.6)	89 (88.1)	**0.010**	256 (45.1)	108 (63.5)	53 (56.4)	**<0.001**
CT Chest	153 (26)	25 (14.7)	13 (12.9)	**<0.001**	27 (4.75)	6 (3.5)	5 (5.3)	0.731
Lung US	8 (1.4)	0 (0)	1 (0.9)	0.306	2 (0.4)	1 (0.6)	0 (0)	0.682
Cardiac Echo	26 (4.4)	3 (1.8)	2 (1.9)	0.223	30 (5.3)	4 (2.4)	3 (3.2)	0.265
infiltrates present in CXR	424 (91.4)	136 (91.3)	84 (94.4)	0.624	244 (97.2)	105 (97.2)	53 (100)	0.723
Interstitial pattern	108 (18.3)	26 (15.3)	24 (23.8)	0.220	58 (10.2)	18 (10.6)	12 (12.8)	0.757
Opacities	320 (54.3)	103 (60.6)	62 (61.4)	0.196	194 (34.2)	80 (47.1)	37 (39.4)	0.009
Multifocal	155 (26.3)	50 (29.4)	30 (29.7)	0.618	79 (13.9)	48 (28.2)	23 (24.5)	**<0.001**
Bilateral	336 (57)	102 (60)	63 (62.4)	0.529	203 (35.7)	90 (52.9)	39 (41.5)	**<0.001**
Pleural effusion	26 (4.4)	6 (3.5)	8 (7.9)	0.216	15 (2.6)	6 (3.5)	4 (4.3)	0.485
CT chest pattern¶								
Ground Glass Opacity (GGO)	104 (17.7)	17 (10)	13 (12.9)	0.038	19 (3.4)	6 (3.5)	5 (5.3)	0.567
Crazy paving	10 (1.7)	1 (0.6)	2 (1.9)	0.565	2 (0.4)	0 (0)	1 (1.1)	0.396
Multifocal	88 (14.9)	14 (8.2)	8 (7.9)	**0.021**	11 (1.9)	3 (1.8)	2 (2.1)	1
Bilateral	134 (22.8)	18 (10.6)	12 (11.9)	**<0.001**	18 (3.2)	6 (3.5)	4 (4.3)	0.76
Lymphadenopathy (LAP)	13 (2.2)	1 (0.6)	1 (0.9)	0.399	3 (0.5)	0 (0)	0 (0)	1
Pleural effusion	17 (2.9)	2 (1.2)	0 (0)	0.120	7 (1.2)	1 (0.6)	0 (0)	0.631
Opacity	49 (8.3)	7 (4.1)	5 (4.9)	0.115	6 (1.1)	0 (0)	0 (0)	0.43
Consolidation	27 (4.6)	1 (0.6)	0 (0)	0.003	3 (0.5)	1 (0.6)	1 (1.1)	0.778
Pulmonary nodules	2 (0.34)	0 (0)	0 (0)	1.000	0 (0)	0 (0)	0 (0)	1
Respiratory Rate- mean (SD)	21.0 (24.2)	29.8 (61.5)	17.9 (4.9)	0.122	23.9 (36.2)	34.2 (75.1)	18.3 (5.6)	0.068
Tidal volume (ml) mean (SD)	432 (121)	439 (114)	444 (97.8)	0.830	432 (113)	419 (108)	442 (93.6)	0.456
PEEP (cm H2O) mean (SD)	11.2 (3.6)	12 (3.9)	11.1 (4.3)	0.359	11.8 (6.4)	12.0 (3.8)	11.5 (3.1)	0.881
Ventilator mode				**<0.001**				**<0.005**
Airway pressure release ventilation (APRV)	6 (1.9)	1 (2)	6 (16.7)		9 (2.5)	1 (0.9)	2 (3.7)	
Pressure control (PC)	49 (15.5)	4 (8)	8 (22.2)		42 (11.5)	5 (4.9)	12 (22.2)	
Pressure Support (PS)	4 (1.3)	1 (2)	1 (2.8)		4 (1.1)	1 (0.9)	1 (1.9)	
Volume control (VC)	206 (65)	22 (44)	16 (44.4)		243 (66.8)	63 (62.4)	32 (59.3)	

Documented ventilator associated pneumonia (VAP)	15 (5.2)	0 (0)	4 (10.5)	**0.045**	13 (3.9)	3 (2.9)	2 (3.7)	1
Documented assessment of spontaneous breathing trial				0.319				0.457
No	145 (50.7)	28 (54.9)	18 (48.6)		180 (54.9)	55 (55)	26 (48.1)	
not indicated	131 (45.8)	22 (43.1)	15 (40.5)		118 (36)	39 (39)	26 (48.1)	
Yes	10 (3.5)	1 (1.9)	4 (10.8)		30 (9.2)	6 (6)	2 (3.7)	

Data presented as n (%) unless otherwise specified

¶ percentage calculated based on available data for patients with computerized tomography (CT) chest scan

Supplementary table 6: SOFA and APCHE-II scores at baseline

	Steroids	IL-6 antagonists	Both	P	N
	N=446	*N=105*	*N=73*		
SOFA Respiration:				.	622
0. >400	19 (4.3)	10 (9.5)	2 (2.8)		
1. < 400 (S:F 221-301), +/- Respiratory support	25 (5.6)	9 (8.6)	6 (8.5)		
2. < 300 (S:F 142-220), +/- Respiratory support	73 (16.4)	19 (18.1)	19 (26.8)		
3. < 200 (S:F 67-141) and Respiratory support	165 (37)	46 (43.8)	26 (36.6)		
4. < 100 (S:F <67) and Respiratory support	164 (36.8)	21 (20)	18 (25.4)		
SOFA coagulation (platelet):				0.407	582
0. >150	338 (83.5)	86 (82.7)	60 (82.2)		
1. < 150	47 (11.6)	11 (10.6)	13 (17.8)		
2. < 100	14 (3.5)	6 (5.8)	0 (0)		
3. < 50	5 (1.2)	1 (0.9)	0 (0)		
4. < 20	1 (0.3)	0 (0)	0 (0)		
SOFA cardiovascular (vasopressors):				.	583
0. No Hypotension	233 (57.5)	60 (57.1)	40 (54.8)		
1. MAP < 70 mm Hg	25 (6.2)	21 (20)	11 (15.1)		
2. Dopamine ≤ 5 or Dobutamine (any dose)	1 (0.3)	0 (0)	1 (1.4)		
3. Dopamine > 5 or Epi/Norepi ≤0.1	70 (17.3)	11 (10.5)	11 (15.1)		
4. Dopamine > 15 or Epi/Norepi > 0.1	76 (18.8)	13 (12.4)	10 (13.7)		
SOFA GCS:				0.012	582
0. 15	176 (43.5)	62 (59)	38 (52.8)		
1. 13-14	37 (9.1)	9 (8.6)	4 (5.6)		
2. 10-12	30 (7.4)	9 (8.6)	6 (8.3)		
3. 6-9	73 (18)	18 (17.1)	16 (22.2)		
4. <6	89 (22)	7 (6.7)	8 (11.1)		
SOFA Liver (bilirubin):				0.156	569

0. < 1.2	335 (84.8)	92 (89.3)	64 (90.1)		
1. 1.2 -1.9 mg/dl ..... 20-32 micromole/L	41 (10.4)	7 (6.8)	2 (2.8)		
2. 2.0 - 5.9 mg/dl ..... 33-101 micromole /L	18 (4.6)	3 (2.9)	4 (5.6)		
3. 6.0-11.9 mg/dl ..... 102-204 micromole /L	1 (0.3)	1 (0.9)	1 (1.4)		
SOFA Renal (creatinine or urine output):				.	583
0. < 1.2 mg/dl (110µmol/L)	254 (62.7)	73 (69.5)	46 (63)		
1. 1.2 -1.9 mg/dl (110-170µmol/L)	77 (19)	21 (20)	15 (20.5)		
2. 2.0 - 2.4 mg/dl (171-299µmol/L)	28 (6.9)	5 (4.8)	6 (8.2)		
3. 2.5-4.9 mg/dl (300-440µmol/L) or urine output < 500 mL/day	30 (7.4)	5 (4.8)	4 (5.5)		
4. > 5.0 mg/dl (>440µmol/L) or urine output < 200 mL/day	16 (3.9)	1 (0.9)	2 (2.7)		
Calculated APACHE II (First 24 hours in ICU that is Day 1 ICU)				<0.001	117
No	23 (46.9)	4 (9.1)	6 (25)		
Yes	26 (53.1)	40 (90.9)	18 (75)		
APACHE II (First 24 hours) score, mean (SD)	18.1 (7.1)	18.2 (6.9)	18.8 (7.9)	0.936	83

Data presented as n (%) unless otherwise specified

Supplementary table 7. ICU support and therapeutic interventions at days 0 of ICU admission after IPTW and matching

	Steroids	IL6-R antagonists	Both	P	SMD
n¶	804.1	582.4	689.6		
Code status change				0.616	0.137
N/A	17 (2.4)	23 (4.0)	11 (1.7)		
No	690 (94.9)	531 (94.7)	624 (94.8)		
Yes	20 (2.8)	7 (1.3)	23 (3.5)		
Code change				0.137	1.284
Changed to 'no chest compression' (no CPR) -DNR	12 (58.6)	3 (40.1)	0 (0)		
Changed to both- DNI-DNR	3 (12.8)	0 (0)	4 (18.0)		
Changed to full support (full code)	6 (28.6)	4 (59.9)	19 (82.0)		
Neuromuscular blocker				0.078	0.423
Atracurium	10 (1.6)	6 (1.6)	30 (6.4)		
Cisatracurium	75 (12.4)	24 (6.2)	26 (5.4)		
Pancuronium	4 (0.6)	0 (0)	0 (0)		
Rocuronium	117 (19.3)	125 (32.6)	125 (26.3)		
Succinylcholine	4 (0.6)	5 (1.2)	12 (2.5)		
Vecuronium	16 (2.7)	12 (3.1)	0 (0)		
None	370 (60.8)	207 (54.0)	277 (58.5)		
Stress ulcer prophylaxis	609 (77.6)	367 (66.9)	462 (70.2)	0.138	0.159
Esomeprazole	22 (3.0)	0 (0)	0 (0)		
Famotidine	141 (19.4)	110 (19.6)	122 (18.7)		
Lansoprazole	20 (2.7)	25 (4.5)	39 (5.9)		
Omeprazole	92 (12.6)	63 (11.2)	98 (14.9)		
Pantoprazole	163 (22.4)	58 (10.3)	175 (26.7)		
Ranitidine	46 (6.3)	0 (0.0)	4 (0.6)		
None	210 (28.9)	223 (39.8)	176 (26.9)		
Not Indicated	30 (4.1)	78 (14.0)	41 (6.2)		
Stress ulcer prophylaxis route (IV)	325 (66.7)	162 (62.4)	287 (65.7)	0.861	0.06
Anticoagulant	687 (85.4)	494 (84.7)	549 (79.6)	0.359	0.102

Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation

¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals

Abbreviation: CPR: Cardiopulmonary resuscitation; DNR: Do-not-resuscitate order; DNI: Do Not Intubate; IV: intravenous

Supplementary table 8. Distribution of Anakinra and Remdesivir doses

Anakinra doses	N (%)
0	851 (99)
1	1 (0.1)
2	3 (0.4)
3	2 (0.2)
4	2 (0.2)
5	1 (0.1)
Remdesivir doses	
0	737 (85.7)
1	24 (2.8)
2	22 (2.6)
3	21 (2.4)
4	27 (3.1)
5	14 (1.6)
6	2 (0.2)
7	2 (0.2)
8	3 (0.4)
9	1 (0.1)
10	6 (0.7)
11	1 (0.1)

Data presented as n (%) unless otherwise specified

Supplementary Table 9. Laboratory parameters at ICU day 0 [unadjusted]

	Steroids	IL-6 antagonists	Both	P overall	N
Blood Glucose (highest)	9.00 [6.82;12.8]	7.39 [5.96;12.2]	7.97 [6.28;13.5]	**0.030**	494
FiO2 % (0.21 to 1.0) Lowest during 24 hours	0.57 [0.40;0.80]	0.44 [0.32;0.62]	0.50 [0.40;0.95]	**0.010**	564
FiO2 % (0.21 to 1.0) Highest during 24 hours	1.00 [0.60;1.00]	0.95 [0.60;1.00]	0.98 [0.74;1.00]	**0.027**	575
FiO2 (0.21 to 1.0) at the time of blood gas	0.80 [0.50;1.00]	0.65 [0.40;0.95]	0.95 [0.52;1.00]	**0.004**	448
Arterial PaO2 at time of FiO2 above in mmHg	70.5 [57.0;95.1]	76.5 [64.8;98.8]	78.2 [66.0;103]	**0.031**	450
Platelets (Thrombocytes) (Lowest within 24 hours)	220 [167;290]	222 [167;277]	211 [164;283]	0.726	550
Alanine Aminotransferase (ALT/SGPT) (highest)	0.57 [0.37;0.93]	0.60 [0.37;1.15]	0.56 [0.43;0.90]	0.560	468
Aspartate aminotransferase (AST/ SGOT) (highest)	0.78 [0.55;1.21]	0.86 [0.63;1.44]	0.85 [0.63;1.25]	0.219	471
Alkaline Phosphatase (Highest within 24 hours)	1.25 [0.90;1.90]	1.24 [1.01;1.57]	1.27 [0.98;1.80]	0.822	352
Total bilirubin (highest)	10.3 [7.10;16.6]	8.55 [5.72;12.0]	10.3 [6.84;12.1]	**0.003**	471
C-reactive protein (CRP) (Highest within 24 hours)	145 [60.3;220]	103 [36.4;200]	132 [65.9;220]	0.261	413
Ferritin (Highest within 24 hours)	1055 [377;1490]	963 [500;1830]	799 [414;1605]	0.405	374
Lactate Dehydrogenase (LDH) levels (Highest within 24 hours)	10.5 [6.94;16.6]	8.57 [7.18;10.9]	8.96 [6.91;11.0]	0.027	341
Leukocyte Count (Lowest)	9.61 [6.50;14.1]	8.00 [5.02;10.8]	9.20 [6.15;11.3]	**0.002**	457
Leukocyte Count (highest)	9.85 [6.60;14.7]	8.10 [5.75;11.3]	9.36 [5.40;13.3]	**0.004**	523
Lymphocyte Count (Lowest within 24 hours)	9.00 [5.00;15.8]	11.6 [8.00;19.9]	10.7 [6.95;16.0]	**0.026**	509
Procalcitonin (Highest within 24 hours)	0.47 [0.19;1.34]	0.24 [0.12;0.44]	0.32 [0.15;0.93]	**<0.001**	299
Fibrinogen Level (Highest within 24 hours)	6.44 [4.98;7.62]	5.82 [5.14;7.38]	6.28 [5.17;7.95]	0.749	217
Interleukin 6 (IL-6) (Highest within 24 hours)	98.8 [34.1;129]	159 [85.2;184]	181 [101;328]	0.219	24

Data presented as median (IQR) . Units presented as SI units as following : PaO2 in mmHg ; ALT/SGPT, AST/SGOT, Alkaline Phosphatase, and Lactate Dehydrogenase (µkat/liter); bilirubin (µmol/liter); Ferritin (mcg/L); leukocytes (×10^9/liter); D-dimer mg/L; Procalcitonin (mcg/L); Fibrinogen (g/L); interleukin 6 (IL-6) (pg/ml); Lactate (mmol/liter); Platelet (x10^9/L)

The following presented as conventional unit: Lymphocyte (% of white blood cells); C-reactive protein (mg/L)

Supplementary Table 10. Laboratory parameters at ICU day 0 after adjustment of covariates

	Steroids	IL6-R antagonists	Both	P value	SMD
N	804.07	572.13	693.34		
Blood Glucose (Highest)	10.47 (5.54)	9.88 (5.13)	10.87 (5.55)	0.549	0.122
FiO2 % (0.21 to 1.0) (Lowest)	0.56 (0.25)	0.52 (0.24)	0.57 (0.24)	0.344	0.145
FiO2 % (0.21 to 1.0) (Highest)	0.79 (0.25)	0.72 (0.26)	0.84 (0.22)	**0.01**	0.33
FiO2 (0.21 to 1.0) at the time of blood gas	0.76 (0.56)	0.62 (0.28)	0.73 (0.26)	**0.024**	0.259
Arterial PaO2 at time of FiO2 above	88.94 (51.19)	84.16 (30.70)	91.54 (47.87)	0.556	0.116
Alanine Aminotransferase (ALT/SGPT) (Highest)	0.82 (0.76)	0.96 (1.25)	0.92 (1.14)	0.663	0.086
Aspartate aminotransferase (AST/ SGOT) (Highest)	1.18 (1.25)	1.29 (1.34)	1.34 (1.74)	0.706	0.074
Alkaline Phosphatase (Highest)	1.49 (0.90)	1.44 (0.77)	1.69 (1.06)	0.429	0.177
Total bilirubin (Highest)	13.85 (11.45)	10.81 (8.43)	13.04 (11.99)	0.033	0.195
C-reactive protein (CRP) (Highest)	144.59 (111.78)	122.95 (108.34)	142.54 (100.90)	0.378	0.134
Ferritin (Highest)	1264.92 (1272.46)	1918.15 (4028.79)	1379.02 (1710.94)	0.402	0.156
Lactate Dehydrogenase (LDH) levels (Highest)	12.66 (8.84)	9.65 (5.03)	9.46 (5.32)	**0.001**	0.298
Leukocyte Count (Lowest)	10.69 (6.39)	8.56 (5.52)	10.10 (4.54)	**0.02**	0.256
Leukocyte Count (Highest)	11.13 (6.65)	9.22 (5.28)	10.78 (5.79)	**0.014**	0.219
Lymphocyte Count (Lowest)	15.79 (19.99)	13.32 (10.84)	13.89 (12.14)	0.276	0.106
D-Dimer	1746.03 (2726.93)	1193.26 (2758.81)	1064.68 (3171.54)	0.195	0.158
Procalcitonin (Highest)	2.20 (5.19)	0.88 (1.98)	1.11 (3.17)	0.018	0.225
Fibrinogen Level (Highest)	6.19 (2.09)	6.17 (1.56)	6.40 (2.01)	0.878	0.078
Interleukin 6 (IL-6) (Highest)	123.27 (162.97)	202.84 (196.81)	283.06 (228.51)	0.314	0.541
Highest lactate	2.44 (2.05)	1.86 (0.78)	2.22 (1.34)	**0.005**	0.273
PF ratio	122.15 (77.81)	136.58 (80.40)	112.08 (56.25)	0.183	0.228
Platelet	235.75 (113.55)	232.32 (113.44)	232.74 (80.57)	0.95	0.022

Data presented as mean (SD) . Units presented as SI units as following : PaO2 in mmHg ; ALT/SGPT, AST/SGOT, Alkaline Phosphatase, and Lactate Dehydrogenase (µkat/liter); bilirubin (µmol/liter); Ferritin (mcg/L); leukocytes (×10^9/liter); D-dimer mg/L; Procalcitonin (mcg/L); Fibrinogen (g/L); interleukin 6 (IL-6) (pg/ml); Lactate (mmol/liter); Platelet (x10^9/L)

presented as conventional unit Lymphocyte (% of white blood cells); C-reactive protein (mg/L)

Abbreviation: PF ratio: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)

Supplementary Table 11: Primary outcomes before matching

	Steroids	IL6-R antagonists	Both	P overall
	N=589	**N=170**	**N=101**	
ICU discharge status				<0.001
Alive	296 (50.3)	118 (69.4)	51 (50.4)	
Deceased	287 (48.7)	50 (30.6)	53 (49.5)	
Hospital discharge status				<0.001
Alive	294 (49.9)	119 (70)	47 (46.5)	
Deceased	295 (50.1)	51 (30)	54 (53.5)	
Ventilation free days, median IQR	18 [10;22]	16.2 [7.50;21.4]	14 [6.4;21]	0.027
Duration of mechanical ventilation (Survivors only)	10.42 [6; 20.5]	13.75 [7.8; 22.1]	14.2 [9.6; 20.8]	0.162
Total ICU length of Stay, median IQR	13.8 [8.00;22.0]	13.4 [8.14;23.8]	17.0 [9.38;24.3]	0.081
Total ICU length of Stay in survivor, median IQR	15.2 [9.00;25.0]	14.0 [8.89;24.0]	18.0 [13.1;25.6]	0.224
Total hospital length of Stay, median IQR	18 [10.6;28.4]	19 [11.0;31]	23.9 [13.1;33]	0.045

Statistical analysis was performed using Chi-square test of independent for ICU discharge and Kruskal-Wallis test for continuous variables

Data presented as n (%) unless otherwise specified

Supplementary Table 12. Cox-proportional hazard model for ICU discharge

Predictors	*Adj HR*	*95% CI*	*p*
Steroids	*Reference*		
IL6-R antagonists	1.36	0.95 – 1.93	0.089
Both	0.85	0.54 – 1.34	0.484
Age (1 year increase)	**0.98**	**0.97 – 0.99**	**0.001**
Weight (kg) at Hospital Admission (1 Kg increase)	**0.99**	**0.99 – 1.00**	**0.017**
sex: Female	*Reference*		
sex: Male	0.76	0.57 – 1.01	0.057
Therapeutic anticoagulation: No	*Reference*		
Therapeutic anticoagulation: Yes	1.28	0.90 – 1.83	0.170
Any anticoagulation: Yes	*Reference*		
Any anticoagulation: No	0.91	0.61 – 1.34	0.619
ethnic group: Hispanic	*Reference*		
ethnic group: Non-Hispanic	0.86	0.61 – 1.22	0.401
Hydroxychloroquine: Yes	*Reference*		
Hydroxychloroquine: No	0.86	0.60 – 1.23	0.404
Fio2 lowest	**0.28**	**0.15 – 0.51**	**<0.001**
Antiviral: Yes	*Reference*		
Antiviral: No	1.18	0.79 – 1.78	0.418
Azithromycin: Yes	*Reference*		
Azithromycin: No	1.07	0.78 – 1.47	0.681
ARDS: No	*Reference*		
ARDS: Mild (P:F 200-300)	0.93	0.41 – 2.12	0.861
ARDS: Moderate (P:F 100-199)	1.27	0.76 – 2.11	0.357
ARDS: Severe (P:F< 100)	0.77	0.48 – 1.22	0.268

Cardiovascular diseases: No	*Reference*		
Cardiovascular diseases: Yes	**0.37**	**0.23 – 0.61**	**<0.001**
URTI: No	*Reference*		
URTI: Yes	1.00	0.68 – 1.47	0.998
Observations	506		
R^2	0.334		

Coefficients < 1 indicate lower hazard of discharge (worse outcome) while coefficients > 1 indicates higher hazard of discharge (better outcome). For example, age was associated with lower hazard of being discharged alive from the ICU (HR = 0.98, P = 0.001) i.e. each one-year increase in age is associated with a 2% decrease in the hazard of ICU discharge. Similarly, higher weight was associated with lower hazard of ICU discharge (HR = 0.99, P = 0.017) i.e. each 1 Kg increase in weight is associated with a 1% decrease in the hazard of ICU discharge. The presence of CVD was associated with lower hazard of ICU discharge (HR = 0.37, P < 0.001)

Abbreviation: ARDS: Acute respiratory distress syndrome ; P:F: ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2); URTI: upper respoiratiory tract infection; HR: hazard ratio; CI: confidence interval

Supplementary table 13 : Association between medication use and mortality after adjustment stratified by steroid dose

Predictors	*Adj Odds Ratios*	*95% CI*	*p*
IL-6R antagonist	*Reference*		
Steroid Low-dose	1.28	0.66 – 2.51	0.464
Steroid High-dose	1.73	0.75 – 4.04	0.203
Age (1 year increase)	1.05	1.03 – 1.07	**<0.001**
Weight (1 Kg increase)	1.00	0.99 – 1.01	0.903
Lowest FiO2	3.20	1.26 – 8.27	**0.015**
Gender			
Female	*Reference*		
Male	1.32	0.82 – 2.15	0.256
Neuromuscular blocker			
Yes	*Reference*		
No	0.87	0.40 – 1.92	0.731
Vasopressors			
Yes	*Reference*		
No	0.88	0.42 – 1.82	0.723
Therapeutic anticoagulation			
No	*Reference*		
Yes	1.41	0.80 – 2.46	0.232
Any anticoagulation			
Yes	*Reference*		
No	0.60	0.31 – 1.16	0.132
Ethnicity			
Hispanic	*Reference*		
Non-Hispanic	1.41	0.79 – 2.55	0.249
Hydroxychloroquine			
Yes	*Reference*		
No	1.16	0.62 – 2.16	0.639
Antivirals			
Yes	*Reference*		
No	0.82	0.44 – 1.54	0.533
Azithromycin			
Yes	*Reference*		
No	1.32	0.78 – 2.22	0.301
ARDS grade			
No	*Reference*		
Mild (P:F 200-300)	0.42	0.07 – 2.20	0.321
Moderate (P:F 100-199)	0.61	0.25 – 1.46	0.269
Severe (P:F< 100)	0.98	0.48 – 1.97	0.947
Cardiovascular diseases			
No	*Reference*		
Yes	2.27	1.29 – 4.08	**0.005**
Asthma/COPD			
No	*Reference*		
Yes	0.94	0.51 – 1.72	0.838

The model was adjusted for the same variables used for IPTW.

Abbreviation: OR: odds ratio; CI: confidence interval; IPTW: Inverse probability

Supplementary Figure 1. Unweighted and weighted Kaplan–Maier estimates for association between treatment ICU LOS



Supplementary Figure 2. Unweighted and weighted Kaplan–Maier estimates for association between treatment and hospital LOS



IL6A donates to IL6-R antagonist

Panel (A) before IPTW and (B) after IPTW

Abbreviation: IPTW: Inverse probability weighting, LOS: length of stay

Supplementary table 14. Documented complication during hospitalization after adjusting for baseline covariates

	Steroids	IL6-R antagonists	Both	p
N¶	804.1	582.4	689.6	
None	35 (4.3)	40 (6.8)	16 (2.3)	0.295
Acute cardiac injury	63 (7.9)	56 (9.6)	33 (4.8)	0.317
Acute kidney injury	292 (36.4)	280 (48.1)	277 (40.2)	0.151
Anemia	155 (19.2)	145 (24.9)	154 (22.3)	0.501
Bacteremia	125 (15.5)	94 (16.2)	87 (12.6)	0.699
Bacterial pneumonia	192 (23.9)	173 (29.7)	197 (28.5)	0.464
Bed ulcers	40 (4.9)	23 (3.9)	28 (4.1)	0.876
Bronchiolitis	1 (0.1)	0 (0)	0 (0)	0.709
Cardiac arrest	155 (19.3)	84 (14.4)	114 (16.5)	0.523
Cardiac arrhythmia new onset	101 (12.6)	67 (11.4)	66 (9.6)	0.72
Cardiomyopathy	27 (3.4)	13 (2.3)	27 (3.9)	0.729
Secondary infection	125 (15.5)	82 (14.1)	93 (13.5)	0.875
Coagulation disorder disseminated intravascular coagulation	34 (4.3)	59 (10.0)	50 (7.3)	0.232
Congestive heart failure	34 (4.3)	15 (2.6)	12 (1.8)	0.404
Deep vein thrombosis	51 (6.3)	59 (10.1)	68 (9.9)	0.336
Empyema	3 (0.3)	5 (0.9)	5 (0.7)	0.702
Endocarditis	0 (0)	6 (1.1)	0 (0)	0.235
Gastrointestinal hemorrhage	29 (3.6)	17 (2.9)	24 (3.5)	0.915
Hepatomegaly	4 (0.5)	0 (0)	0 (0)	0.414
High bnp nt pro bnp	34 (4.2)	29 (4.9)	34 (4.9)	0.908
High troponin i t high sensitivity	**97 (12.1)**	**57 (9.8)**	**134 (19.4)**	**0.043**
Hyperglycemia	200 (24.9)	161 (27.7)	206 (29.8)	0.621
Hypoglycemia	31 (3.9)	6 (1.0)	27 (3.9)	0.252
Liver dysfunction/ Acute liver failure	**118 (14.6)**	**139 (23.9)**	**82 (11.9)**	**0.038**
Lung abscesses	3 (0.3)	0 (0)	5 (0.7)	0.448
Meningitis encephalitis	15 (1.8)	3 (0.5)	0 (0)	0.065
Myocarditis	8 (1.0)	7 (1.3)	0 (0)	0.281
Pancreatitis	2 (0.2)	0 (0)	0 (0)	0.67
Pleural effusions	54 (6.7)	63 (10.7)	24 (3.5)	0.069
Pleurisy	2 (0.2)	3 (0.4)	0 (0)	0.469
Pneumothorax	54 (6.8)	35 (6.0)	30 (4.4)	0.64
Respiratory failure (ARDS)	520 (64.7)	315 (54.1)	460 (66.7)	0.108
Rhabdomyolysis myositis	20 (2.5)	20 (3.3)	11 (1.6)	0.574
Seizure	17 (2.2)	11 (1.9)	7 (1.0)	0.689

Septic shock	300 (37.3)	279 (48.0)	307 (44.4)	0.192
Splenomegaly	3 (0.4)	4 (0.7)	0 (0)	0.303
St elevations in ECG	8 (1.0)	9 (1.6)	0 (0)	0.096
Stroke or cerebrovascular accident	25 (3.1)	16 (2.8)	10 (1.4)	0.711

Data presented as n (%) unless otherwise specified. N (%) may differ due to approximation
¶ Each individual gets its own weight that is used for further analysis. Multiplication by these weights can usually results in decimals

Supplementary table 15: Causative microbiology and rate of secondary infections across the groups

	Steroids	IL-6 antagonists	Both	P
Respiratory Viral Panel (RVP) PCR Positive¶	1 (0.2)	2 (1.2)	0 (0)	0.721
HIV Positive	2 (0.3)	3 (1.8)	1 (0.9)	0.093
Hepatitis B Positive	9 (1.5)	9 (5.3)	2 (1.9)	0.019
Hepatitis C Positive	11 (1.9)	1 (0)	1 (0.9)	0.621
Cytomegalovirus PCR Positive	2 (0.3)	0 (0)	1 (0.9)	0.401
Legionella Urine Ag Positive	0 (0)	1 (0.6)	0 (0)	0.315
Blood Cultures Positive #	93 (21.9)	27 (17.2)	17 (19.3)	0.436
Which Hospital Day(s) Positive Blood Cultures Performed? Median [IQR]	7 [0.25;14]	14[1;22]	10 [0.75;13]	0.138
Sputum Culture Positive $	167 (50.6)	65 (53.3)	34 (45.9)	0.609
Which Hospital Day(s) Positive Sputum Culture Performed? Median [IQR]	4 [1;11]	5[1.5;9]	5 [1;13.5]	0.868
Urine Culture Positive? *	74 (29.2)	23 (20.2)	11 (19.6)	0.101
Overall Bacterial super infection	87 (14.8)	27 (15.9)	15 (14.9)	0.904

¶ performed in 127 steroids group, 85 IL6-R antagonist group, 33 combination group

Performed in 424 steroids group, 157 IL6-R antagonist group, 88 combination group

$ Performed in 331 steroids group, 121 -R antagonist group, 74 combination group

* Performed in 254 steroids group, 114 -R antagonist group, 56 combination group

Data presented as n (%) unless otherwise specified

Supplementary table 16. Linear mixed modelling of PF ratio

Predictors	ß	*95 %CI*	*p*
Steroids	*Reference*		
IL-6R antagonists Both	8.68 -1.51	-6.67 – 24.02 -18.30 – 15.28	0.268 0.860
ICU day	1.30	0.42 – 2.18	**0.004**
sex: Male	-7.64	-17.67 – 2.38	0.135
Age (1 year increase)	-0.30	-0.67 – 0.07	0.112
Weight(kg)at Hospital Admission (1 Kg increase)	-0.31	-0.48 – -0.13	**0.001**
therapeutic anticoagulation: Yes	-6.12	-15.92 – 3.67	0.221
Any anticoagulation: Yes vs. No	-0.56	-14.92 – 13.80	0.939
ethnic group: Non-Hispanic	-2.46	-15.04 – 10.12	0.701
med hydroxychloroquine: No	-6.73	-17.76 – 4.29	0.231
med antiviral: No	5.57	-5.01 – 16.15	0.302
med azithromycin: No	10.74	1.44 – 20.04	**0.024**
ARDS: Mild(P:F 200-300) ARDS: Moderate(P:F 100-199) ARDS: Severe(P:F<100)¶	15.11 3.82 -33.64	-14.74 – 44.97 -14.70 – 22.34 -47.96 – -19.32	0.321 0.686 **<0.001**
CVD: Yes	6.32	-6.09 – 18.72	0.318
Asthma/COPD: Yes	-5.93	-19.29 – 7.43	0.384
Respiratory failure: No	0.99	-11.34 – 13.31	0.875
IL-6 antagonists x ICU day Both meds x ICU day *	1.12 0.96	-1.30 – 3.55 -1.06 – 2.97	0.364 0.352

ß: estimate represents average change in PFO2 for each 1 unit change in the predictor i.e. the increase in the PF ratio for each 1 unit increase in the predictor for IL-6R antagonists, steroids, and combination group.

Linear mixed modelling is similar to linear regression. The coefficients represent the change in the outcome for each 1 unit change if the predictor is continuous. If the predictor is categorical, it represents the average change between the specified level and the reference category

¶The -33.64 means that the average PF ratio is lower by 33.64 in patients with severe ARDS compared to patients with no ARDS

* This represents the average change in PF ratio per day in each of these groups for each 1 day increase in the ICU stay. for example, the 1.12 means that the average increase in the PF ration (per day) in patients who received both meds is higher by 1.12 units compared to patients who received steroids

Linear mixed modeling considers clustering within patients. Time was included as the main effect of the model. The same covariates used for MSM were used in the mixed model to ensure consistency. PF ratio data were available for 482 patients. Estimated marginal trends were used to visualize the change in the ratio after adjusting for baseline factors (e.g., age and sex) and time-varying covariates, such as the use of anticoagulation. Missing values were not imputed. The interaction between time and medication use was also included in the model to assess whether the change in the PF ratio was significantly different between the groups.

Supplementary Figure 2. Estimated marginal trend for the change in PF ratio across groups.



Supplementary table 16 :Change in lab values

Linear mixed modelling was used to assess whether the change in lab values across time was significantly different between groups. The interaction between time and medication was included in the model. The same variables used for IPTW were used for the analysis. Only results for the interaction are shown.

	ß	SE	t	p
CRP (n = 247)				
IL-6R antagonist	-0.98	1.8	-0.55	0.58
Both	-3.39	1.64	-2.07	**0.04**
Lowest lymphocyte (n = 372)				
IL-6R antagonist	0.19	0.25	0.76	0.45
Both	0.13	0.23	0.59	0.56
Lowest leukocyte (n = 352)				
IL-6R antagonist	0.2	0.1	1.97	**0.049**
Both	0.07	0.09	0.78	0.43
Highest LDH (n = 205)				
IL-6R antagonist	0.01	0.12	0.12	0.91
Both	0.02	0.12	0.19	0.85
Ferritin (n = 220)				
IL-6R antagonist	-51.65	24.67	-2.09	**0.04**
Both	-32.19	19.77	-1.63	0.1
Data for IL-6 was not sufficient N represents the number of available patients for the analysis				

Supplementary table 17 : Need for inotropes to day 28

	Steroids	IL-6 antagonists	Both	P
	N=589	***N=170***	***N=101***	
None:	462 (78.4)	153 (90)	91 (90.1)	<0.001
Angiotensin II	5 (0.9)	1 (0.6)	0 (0)	1.000
Dobutamine	25 (4.2)	2 (1.2)	6 (5.9)	0.070
Dopamine	16 (2.7)	7 (4.1)	2 (1.9)	0.599
Droxidopa	1 (0.2)	1 (0.6)	0 (0)	0.531
Epinephrine	55 (9.3)	8 (4.7)	13 (12.9)	0.054
Isoproterenol	2 (0.3)	0 (0)	1 (0.9)	0.401
Milrinone	13 (2.2)	1 (0.6)	1 (0.9)	0.399
Norepinephrine	386 (65.5)	127 (74.7)	82 (81.2)	0.002
Phenylephrine	47 (7.9)	26 (15.3)	14 (13.9)	0.009
Vasopressin	137 (23.3)	38 (22.4)	22 (21.8)	0.931
Trelipressin	2 (0.3)	0 (0)	1 (0.9)	0.401

Data presented as n (%)

Supplementary File 2: Collaborative Co-Author List.

¥ On behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group

Belgium
Centre Hospitalier Jolimont: Jean-Baptiste Mesland, Pierre Henin, Hélène Petre, Isabelle Buelens, Anne-Catherine Gerard
The Brugmann University hospital, Bruxelles: Philippe Clevenbergh

Bosnia and Herzegovina
University Clinical Hospital, Mostar, Bosnia and Herzegovina: Dragana Markotić, Ivana Bošnjak

Columbia
Clinica Medical SAS: Oscar Y Gavidia, Felipe Pachon, Yeimy A Sanchez

Croatia
Clinical Hospital Center Rijeka, Rijeka, Croatia: Danijel knežević

Egypt
Helwan University: Mohamed El Kassas, Mohamed Badr, Ahmed Tawheed, Ahmed Tawheed, Hend Yahia

Hondurus
Honduras Medical Center: Jose Luis Ramos Coello, Guillermo Perez, Ana Karen Vallecillo Lizardo, Gabina María Reyes Guillen, Helin Archaga Soto

Hungary
Uzsoki Teaching Hospital: Csaba Kopitkó, Ágnes Bencze,István Méhész, Zsófia Gerendai,

India
Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry: Anusha Cherian, Sreejith Parameswaran , Magesh Parthiban, Menu Priya A.
Maulana Azad Medical College and Lok Nayak hospital: Mradul Kumar Daga, Munisha Agarwal , Ishan Rohtagi

Japan
Center Hospital of the National Center for Global Health and Medicine: Wataru Matsuda, Reina Suzuki
Sapporo City General Hospital: Yuki Itagaki, Akira Kodate, Reina Suzuki, Akira Kodate,Yuki Takahashi, Koyo Moriki
Tokyo Medical and Dental University: Hidenobu Shigemitsu, Yuka Mishima, Nobuyuki Nosaka, Michio Nagashima
Hiroshima University: Michihito Kyo

Mexico
Hospital Universitario, Universidad Autonoma de Nuevo León: Rene Rodriguez-Gutierrez, Jose Gerardo Gonzalez-Gonzalez, Alejandro Salcido-Montenegro, Adrian Camacho-Ortiz

Pakistan
Dow University Hospital: Muhammad Sohaib Asghar, Mashaal Syed, Syed Anosh Ali Naqvi

Russia
Kuban State Medical University with affiliation Territorial Hospital #2: Igor Borisovich Zabolotskikh, Konstantin Dmitrievich Zybin, Sergey Vasilevich Sinkov, Tatiana Sergeevna Musaeva

Saudi Arabia
King Saud University: Mohammed A Almazyad, Mohammed I Alarifi, Jara M Macarambon, Ahmad Abdullah Bukhari, Hussain A. Albahrani, Kazi N Asfina, Kaltham M Aldossary
King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center: Yaseen M Arabi, Sheryl Ann Abdukahil
King Fahad Armed Forces Hospital: Razan K Alamoudi, Hassan M. AlSharif, Sarah A. Almazwaghi, Mohammed S Elsakran, Mohamed A Aid, Mouaz A Darwich, Omnia M Hagag, Salah A Ali, Alona rocacorba, Kathrine Supeña, Efren Ray Juane, Jenalyn Medina, Jowany Baduria
King Faisal Specialist Hospital & Research Centre - Riyadh: Marwa Ridha Amer, Mohammed Abdullah Bawazeer, Khalid Maghrabi, Abid Shahzad Butt, Talal I. Dahhan, Eiad Kseibi, Syed Moazzum Khurshid, Muath Rabee, Mohammed Abujazar, Razan Alghunaim, Maal Abualkhair, Abeer Turki AlFirm, Ali Al-Janoubi

Serbia
UMC Zvezdara, Belgrad: Bojan Kovacevic, Jovana Bojicic
Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica: Ana Andrijevic, Srdjan Gavrilovic, Vladimir Carapic

Spain
Hospital Universitario La Paz: Santiago Y. Teruel, Belen C. Martin, Santiago Y. Teruel

United States
Boston University School of Medicine, Boston, MA: Allan J. Walkey, Sushrut S. Waikar, Michael A. Garcia, Mia Colona, Zoe Kibbelaar, Michael Leong, Daniel Wallman, Kanupriya Soni, Jennifer Maccarone, Joshua Gilman, Ycar Devis, Joseph Chung, Munizay Paracha, David N. Lumelsky, Madeline DiLorenzo, Najla Abdurrahman, Shelsey Johnson
Albany Medical Center: Suzanne Barry, Christopher Woll, Gregory Wu, Erin Carrole, Kathryn Burke, Mustafa Mohammed
AnMed Health: Abhijit A Raval, Andrea Franks
Ascension St.Vincent Hospital: Anmol Kharbanda, Sunil Jhajhria, Zachary Fyffe
Ascension/St. Thomas Research Institute West Campus: Stephen Capizzi, Bethany Alicie, Martha Green, Lori Crockarell, Amelia Drennan, Kathleen Dubuque, Tonya Fambrough, Nikole Gasaway, Briana Krantz, Peiman Nebi, Jan Orga, Margaret Serfass, Alina Simion, Kimberly Warren, Cassie Wheeler, CJ Woolman
Augusta Health: Andrew S. Moyer, George M. Verghese
Augusta University Medical Center: Andrea Sikora Newsome, Christy C. Forehand, Rebecca Bruning, Timothy W. Jones

Banner University Medical Center-Tucson: Jarrod M Mosier, Karen Lutrick, Beth Salvagio Campbell, Cathleen Wilson, Patrick Rivers, Jonathan Brinks, Mokenge Ndiva Mongoh, Boris Gilson
Baylor College of Medicine, Baylor St. Lukes Medical Center: Christopher M Howard, Cameron McBride, Jocelyn Abraham, Orlando Garner, Katherine Richards, Keegan Collins, Preethi Antony, Sindhu Mathew
Baylor Scott & White Health: Valerie C. Danesh, Gueorgui Dubrocq, Amber L. Davis, Marissa J Hammers, ill M. McGahey, Amanda C. Farris, Elisa Priest, Robyn Korsmo, Lorie Fares, Kathy Skiles, Susan M. Shor, Kenya Burns, Corrie A Dowell, Gabriela "Hope" Gonzales, Melody Flores, Lindsay Newman, Debora A Wilk, Jason Ettlinger, Jaccallene Bomar, Himani Darji, Alejandro Arroliga, Alejandro C Arroliga, Corrie A. Dowell, Gabriela Hope Conzales, Melody Flores, Lindsay Newman, Debora A. Wilk, Jason Ettlinger, Himani Darji, Jaccallene Bomar
Beth Israel Deaconess Medical Center: Valerie M. Banner-Goodspeed, Somnath Bose, Lauren E. Kelly, Melisa Joseph, Marie McGourty, Krystal Capers, Benjamin Hoenig, Maria C. Karamourtopoulos, Anica C. Law, Elias N. Baedorf Kassis
Cedars Sinai Medical Center: Pooja A. Nawathe, Isabel Pedraza, Jennifer Tsing, Karen Carr, Anila Chaudhary, Kathleen Guglielmino
Chambersburg Hospital: Raghavendra Tirupathi, Alymer Tang, Arshad Safi, Cindy Green, Jackie Newell
Children's Hospital Colorado, University of Colorado Anschutz Medical Campus: Katja M. Gist, Imran A Sayed, John Brinton, Larisa Strom
Children's Hospital of Philadelphia: Kathleen Chiotos, Allison M. Blatz, Giyoung Lee, Ryan H. Burnett, Guy I. Sydney, Danielle M. Traynor
Cox Medical Center Springfield: Steven K. Daugherty, Sam Atkinson, Kelly Shrimpton
Detar Family Medicine residency: Sidney Ontai, Brian Contreras, MD, Uzoma Obinwanko, Nneka Amamasi, Amir Sharafi
Detroit Medical Centre: Sarah Lee, Zahia Esber, Chetna Jinjvadia
George Washington University: David P. Yamane, Ivy Benjenk, Nivedita Prasanna
Howard University Hospital: Orma Smalls
Jacobs Medical Center UC San Diego Health – La Jolla: Atul Malhotra, Abdurrahman Husain, Qais Zawaydeh
JPS Health Network: Steven Q. Davis, Valentina Jovic, Valentina Jovic, Max Masuda, Amanda Hayes
Lakes Region General Hospital: Michael Smith, William Snow, Riley Liptak, Hannah Durant, Valerie Pendleton, Alay Nanavati, Risa Mrozowsk
LifeBridge Health/Sinai and Northwest Hospitals: Namrata Nag, Jeff Brauer, Ashwin Dharmadhikari, Sahib Singh, Franco Laghi,
Ghania Naeem, Andrew Wang, Kevin Bliden, Amit Rout, Jaime Barnes, Martin Gesheff, Asha Thomas, Melbin Thomas, Alicia R. Liendo, Jovan Milosavljevic, Kenan Abbasi, Nicholas B. Burley, Nicole Rapista, Samuel Amankwah, Sanjay K Poudel, Saroj Timilsina, Sauradeep Sarkar, Oluwasayo Akinyosoye, Shashi K. Yalamanchili, Sheena Moorthy, Sonia Sugumar, Jonathan Ford, Martin C. Taylor, Charlotte Dunderdale, Alyssa Henshaw, Mary K. Brunk, Jessica Hagy,
Shehryar Masood, Sushrutha Sridhar
Loyola University Medical Center: Yuk Ming Liu, Sarah Zavala, Sarah Zavala, Esther Shim
M Health-Fairview, University of Minnesota: Ronald A. Reilkoff, Julia A. Heneghan, Sarah Eichen, Lexie Goertzen, Scott Rajala, Ghislaine Feussom, Ben Tang
MacNeal Hospital Loyola Medicine: Christine C. Junia, Robert Lichtenberg, Hasrat Sidhu, Diana Espinoza, Shelden Rodrigues, Maria Jose Zabala, Daniela Goyes, Ammu Susheela, Buddhi Hatharaliyadda, Naveen Rameshkumar, Amulya Kasireddy, Genessis Maldonado, Lisseth Beltran, Akshata Chaugule, Hassan Khan
Mayo Clinic Arizona: Rodrigo Cartin-Ceba, Ayan Sen, Amanda Palacios, Giyth M. Mahdi

Mayo Clinic Rochester: Rahul Kashyap, Ognjen Gajic, Vikas Bansal, Aysun Tekin, Amos Lal, John C. O'Horo, Neha N. Deo, Mayank Sharma, Shahraz Qamar, Cory J. Kudrna , Juan Pablo Domecq
Mayo Clinic, Eau Claire: Abigail T. La Nou, Marija Bogojevic
Mayo Clinic, Florida: Devang Sanghavi, Pramod Guru, Karthik Gnanapandithan, Hollie Saunders, Zachary Fleissner, Juan Garcia , Alejandra Yu Lee Mateus, Siva Naga Yarrarapu
Mayo Clinic, Mankato: Syed Anjum Khan, Nitesh Kumar Jain, Thoyaja Koritala
Medical Center Health System, Odessa: Alexander Bastidas, Gabriela Orellana, Adriana Briceno Bierwirth, Eliana Milazzo, Juan Guillermo Sierra, Thao Dang
Medical Center Navicent Health: Amy B. Christie, Dennis W. Ashley, Rajani Adiga
Mercy Hospital and Medical Center, Chicago: Travis Yamanaka, Nicholas A. Barreras, Michael Markos, Anita Fareeduddin, Rohan Mehta
Mercy Hospital, Saint Louis: Chakradhar Venkata, Miriam Engemann, Annamarie Mantese
Millard Fillmore Suburban Hospital: Anna Eschler, Mary Hejna, Emily Lewandowski, Kristen Kusmierski, Clare Martin
Montefiore Medical Center The Bronx: Jen-Ting Chen, Aluko Hope, Zoe Tsagaris, Elise Ruen, Aram Hambardzumyan
OSF Saint Francis Medical Center: Bhagat S. Aulakh, Sandeep Tripathi, Jennifer A. Bandy, Lisa M. Kreps, Dawn R. Bollinger, Jennifer A. Bandy
OSF Saint Francis Medical Center: Bhagat S. Aulakh, Sandeep Tripathi, Jennifer A. Bandy, Lisa M. Kreps, Dawn R. Bollinger, Jennifer A. Bandy
Parkview Health System, Fort Wayne: Roger Scott Stienecker, Andre G. Melendez, Tressa A. Brunner, Sue M Budzon, Jessica L. Heffernan, Janelle M. Souder, Tracy L. Miller, Andrea G. Maisonneuve
Samaritan Health Services: Brian L. Delmonaco, Anthony Franklin, Mitchell Heath
Sarasota Memorial Hospital: Antonia L. Vilella, Sara B. Kutner, Kacie Clark, Danielle Moore
St. Joseph's Candler Health System: Howard A. Zaren, Stephanie J. Smith, Grant C. Lewis, Lauren Seames, Cheryl Farlow, Judy Miller, Gloria Broadstreet
St.Mary Medical Center, Langhorne: Umang Patel, Jordesha Hodge, KrunalKumar Patel, Shivani Dalal, Himanshu Kavani, Sam Joseph
Stamford Health: Michael A. Bernstein, Ian K. Goff, Matthew Naftilan, Amal Mathew, Deborah Williams, Sue Murdock, RN, Maryanne Ducey, Kerianne Nelson
Stanford Hospital and Clinics: Paul K Mohabir, Connor G O'Brien, Komal Dasani
The Children's Hospital at OU Medicine: Neha Gupta, Tracy L Jones, Shonda C Ayers, Amy B Harrell, Dr. Brent R Brown
The University of Tennessee Medical Center: Megan Edwards, Caleb Darby, Kristy Page, Amanda Brown, Jessie McAbee
Thomas Jefferson University Hospital: Katherine A. Belden, Michael Baram, Devin M. Weber, Rosalie DePaola, Yuwei Xia, Hudson Carter, Aaron Tolley, Mary Barletta
Truman Medical Centers: Mark Steele, Laurie Kemble
Tulane University Medical Center and University Medical Center New Orleans: Joshua L. Denson, A. Scott Gillet, Margo Brown, Rachael Stevens, Andrew Wetherbie, Kevin Tea, Mathew Moore
UNC Medical Center: Benjamin J Sines, Thomas J Bice
University Medical Center of Southern Nevada Las Vegas; University of Nevada, Las Vegas: Rajany V. Dy, Alfredo Iardino, Jill Sharma, Julia Christopher, Marwan Mashina, Kushal Patel
University of Alabama at Birmingham: Erica C. Bjornstad, Nancy M. Tofil, Scott House, Isabella Aldana
University of Arkansas for Medical Sciences: Nikhil K. Meena, Jose D. Caceres, Nikhil K Meena, Sarenthia M. Epps, Harmeen Goraya, Kelsey R. Besett, MD, Ryan James, Lana Y. Abusalem, Akash K. Patel, Lana S Hasan
University of Cincinnati: Dina Gomaa B.S., Michael Goodman, Devin Wakefield, Anthony Spuzzillo, John O. Shinn II

University of Iowa Carver College of Medicine: Patrick W. McGonagill, Colette Galet, Janice Hubbard, David Wang, Lauren Allan, Aditya Badheka, Madhuradhar Chegondi
University of Kansas Medical Center: Usman Nazir, Garrett Rampon, Jake Riggle, Nathan Dismang
University of Louisville Hospital: Ozan Akca, Rainer Lenhardt, Rodrigo S. Cavallazzi, Ann Jerde, Alexa Black, Allison Polidori, Haily Griffey, Justin Winkler, Thomas Brenzel
University of Michigan Health System: Pauline Park, Andrew Admon, Sinan Hanna, Rishi Chanderraj, Maria Pliakas, Ann Wolski, Jennifer Cirino
University of Missouri, Columbia: Dima Dandachi, Hariharan Regunath, Maraya N. Camazine, Grant. E. Geiger, Abdoulie O. Njai, Baraa M. Saad
University of Vermont Larner College of Medicine: Renee D. Stapleton, Anne E. Dixon, Olivia Johnson, Sara S. Ardren, Stephanie Burns, Anna Raymond, Erika Gonyaw, Kevin Hodgdon, Chloe Housenger, Benjamin Lin, Karen McQuesten, Heidi Pecott-Grimm, Julie Sweet, Sebastian Ventrone
Wake Forest University School of Medicine; Wake Forest Baptist Health Network: Ashish K. Khanna, Lynne Harris, Bruce Cusson, Jacob Fowler, David Vaneenenaam, Glen McKinney, Imoh Udoh, Kathleen Johnson
Yale New Haven Health New Haven: Kevin Sheth, Abdalla Ammar, Mahmoud Ammar, Victor Torres Lopez , Charles Dela Cruz, Akhil Khosla, Samir Gautam